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A B S T R A C T
Background
Drusen are amorphous yellowish deposits beneath the sensory retina. People with drusen, particularly large drusen, are at higher risk
of developing age-related macular degeneration (AMD). The most common complication in AMD is choroidal neovascularisation
(CNV), the growth of new blood vessels in the centre of the macula. The risk of CNV is higher among people who are already affected
by CNV in one eye.
It has been observed clinically that laser photocoagulation of drusen leads to their disappearance and may prevent the occurrence of
advanced disease (CNV or geographic atrophy) associated with visual loss.
Objectives
To examine the effectiveness and adverse effects of laser photocoagulation of drusen in AMD.
Search methods
We searchedCENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2015, Issue 7), OvidMEDLINE, Ovid
MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to August
2015), EMBASE (January 1980 to August 2015), Latin American and Caribbean Health Sciences Literature Database (LILACS) (Jan-
uary 1982 to August 2015), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov)
and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en).
We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 3
August 2015.
Selection criteria
Randomised controlled trials (RCTs) of laser treatment of drusen in AMD in which laser treatment had been compared with no
intervention or sham treatment. Two types of trials were included. Some trials studied one eye of each participant (unilateral studies);
other studies recruited participants with bilateral drusen and randomised one eye to photocoagulation or control and the fellow eye to
the other group.
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Data collection and analysis
Two review authors independently selected studies and extracted data. We pooled data from unilateral and bilateral studies using a
random-effects model. For the bilateral studies, we estimated the within-person correlation coefficient from one study and assumed it
was valid for the others.
Main results
The update of this review found two additional studies, totaling 11 studies that randomised 2159 participants (3580 eyes) and followed
them up to two years, of which six studies (1454 participants) included people with one eye randomised to treatment and one to
control. Studies were conducted in Australia, Europe and North America.
Overall, the risk of bias in the included studies was low, particularly for the larger studies and for the primary outcome development
of CNV. Photocoagulation did not reduce the development of CNV at two years’ follow-up (odds ratio (OR) 1.07, 95% confidence
interval (CI) 0.79 to 1.46, 11 studies, 2159 participants (3580 eyes), high quality evidence). This estimate means that, given an overall
occurrence of CNV of 8.3% in the control group, we estimated an absolute risk reduction by no more than 1.4% in the laser group,
according to the lower CI limit. Only two studies investigated the effect on the development of geographic atrophy and could not
show a difference, but estimates were imprecise (OR 1.30, 95% CI 0.38 to 4.51, two studies, 148 participants (148 eyes), low quality
evidence).
Among secondary outcomes, photocoagulation led to drusen reduction (OR 9.16, 95% CI 6.28 to 13.4, three studies, 570 participants
(944 eyes), high quality evidence) but was not shown to limit loss of 3 or more lines of visual acuity (OR 0.99, 95% CI 0.81 to 1.22,
nine studies, 2002 participants (2386 eyes), moderate quality evidence).
In a subgroup analysis, no difference could be shown for conventional visible (eight studies) versus subthreshold invisible (four studies)
photocoagulation for the primary outcomes (P value = 0.29). The effect in the subthreshold group did not suggest a relevant benefit
(OR 1.27, 95% CI 0.82 to 1.98). No study used micropulse subthreshold photocoagulation.
No other adverse effects (apart from development of CNV, geographic atrophy or visual loss) were reported.
Authors’ conclusions
The trials included in this review confirm the clinical observation that laser photocoagulation of drusen leads to their disappearance.
However, treatment does not result in a reduction in the risk of developing CNV, and was not shown to limit the occurrence of
geographic atrophy or visual acuity loss.
Ongoing studies are being conducted to assess whether the use of extremely short laser pulses (i.e. nanosecond laser treatment) cannot
only lead to drusen regression but also prevent neovascular AMD.
P L A I N L A N G U A G E S U M M A R Y
Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Review question
We reviewed the evidence about the effect of laser treatment of the centre of the retina in people with macular drusen to prevent the
occurrence of the more advanced type of age-related macular degeneration (AMD).
Background
Drusen are yellowish deposits that can be seen in the macula (the centre of the retina) in a larger proportion of people as they get
older. People with drusen, particularly extensive large drusen, are at higher risk of developing AMD. The most common complications
in AMD are the growth of new blood vessels in the centre of the macula (called choroidal neovascularisation (CNV), also known as
’wet AMD’) and loss of retinal cells or photoreceptors in the macula (called geographic atrophy). It has been observed clinically that
making very small burns around the macula with laser light (laser photocoagulation) makes drusen disappear. Laser photocoagulation
of drusen has thus been proposed as a way to prevent the development of CNV and geographic atrophy. More recently, subthreshold
photocoagulation has been used to cause invisible laser burns and achieve drusen reduction with less damage to the retinal structure.
Search date
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The evidence is current to 3 August 2015.
Study characteristics
This review included data from 11 trials conducted in Australia, Europe and North America. The studies followed up 2159 participants
with drusen (3580 eyes) to two years, of which six studies (1454 participants) included people with one eye randomised to treatment
and one to control. Four studies (850 eyes) used subthreshold photocoagulation.
Study funding sources
Three out of four studies using laser subthreshold photocoagulation were sponsored by the laser producer.
Key results
These studies showed that laser photocoagulation of drusen leads to their disappearance. However, laser photocoagulation of drusen
did not reduce the risk of developing CNV, which was about 10% at three years in untreated participants. A smaller number of studies
reported on the development of geographic atrophy, that is, atrophy in the centre of the macula, but these studies were inconclusive
and the effect of laser treatment of drusen on the development of geographic atrophy was uncertain. The risk of visual loss was similar
in treated and untreated groups. There was no suggestion that a benefit may exist with subthreshold photocoagulation.
Quality of the evidence
The overall quality of the evidence was high regarding failure to prevent CNV, but it was low for prevention of atrophy due to the
small number of participants for whom this outcome was assessed.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Outcomes at two years Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(eyes, studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Photocoagulation
Development of CNV 83 per 1000 89 per 1000
(67 to 117)
OR 1.07
(0.79 to 1.46)
2159 (3580 eyes, 11 studies) ⊕⊕⊕⊕
high1
Low risk population (people with bilateral drusen)
50 per 1000 54 per 1000
(40 to 73)
High risk population (people with CNV in the fellow eye)
250 per 1000 268 per 1000
(199 to 365)
Development of geographic
atrophy
66 per 1000 84 per 1000
(26 to 241)
OR 1.3
(0.38 to 4.51)
148
(148 eyes, 2 studies)
⊕⊕©©
low2
Visual loss of 2-3+ lines of
visual acuity
150 per 1000 149 per 1000
(122 to 183)
OR 0.99
(0.81 to 1.22)
2002 (3486 eyes, 9 studies) ⊕⊕⊕©
moderate3
Loss of ≥ 0.3 log units of
contrast sensitivity
119 per 1000 100 per 1000
(26 to 309)
OR 0.82
(0.20 to 3.31)
82
(82 eyes, 1 study)
⊕⊕©©
low2
Reading speed in words/
minute
The mean reading speed in
words/ m inute in the control
groups was
100 words/ minute
The mean reading speed in
words/ m inute in the inter-
vent ion groups was
12.5 lower
(7.2 lower to 32.2 higher)
- 44
(44 eyes, 1 study)
⊕⊕©©
low2
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Drusen reduction 107 per 1000 522 per 1000
(428 to 614)
OR 9.16
(6.28 to 13.4)
570
(944 eyes, 3 studies)
⊕⊕⊕⊕
high4,5
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; CNV: choroidal neovascularisat ion; OR: odds rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Allocat ion sequence generat ion and allocat ion concealment and masking of visual acuity outcome assessors was achieved
in half or less of them; however, the larger studies in this meta-analysis were good quality. Other quality items were not a
problem for the primary outcome (no downgrade).
2Small study yielding wide 95% conf idence intervals (-2 for imprecision).
3Visual acuity examiners were masked in less than half of studies (-1 for risk of bias).
4The three studies included in this analysis had low risk of bias (no downgrade).
5Estimates were heterogeneous but they both suggest a strong ef fect (no downgrade).
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B A C K G R O U N D
Description of the condition
Age-related macular degeneration (AMD) is the leading cause
of vision loss in industrialised countries (Klein 2004; Vingerling
1996). Early AMD is characterised by focal or diffuse depositing
of extracellular material between the retinal pigment epithelium
(RPE) and Bruch’s membrane, forming drusen (focal deposits)
or basal laminar deposits (diffuse deposits) (Bressler 1994; Sarks
1999; Young 1987). This process is associated with progressive de-
generation of PRE and photoreceptor cells (Guidry 2002; Phipps
2003; Young 1987). Advanced AMD is characterised by the devel-
opment of geographic atrophy (characterising the non-exudative
AMD form) or choroidal neovascularisation (CNV; characterising
the exudative AMD). When the fovea, which represents the centre
of vision, is involved by atrophic or exudative manifestations of
AMD, a severe visual loss results.
Advanced AMD has a prevalence that increases markedly with
age (EDPRG 2004; Owen 2003). In the US, advanced AMD
prevalence is 3.5% in white men and 4% in white women at 75
to 79 years (EDPRG 2004). Based on one systematic review of
UK studies, Owen 2003 reported that there were approximately
214,000 people with visual impairment caused by AMD. In this
study, the ratio of neovascular AMD to geographic atrophy was
about 2 : 1, such as in Smith 2001. Ten years later, Owen 2012
estimated 513.000 prevalent cases of late AMD, of which 263,000
were neovascular AMD. Rudnicka 2015 conducted a systematic
review and estimated 293.000 incident cases of late AMD each
year in the U.S.A.
Drusen results from deposition of the photoreceptors debris,
which are composed of lipofuscin and membranous deposits.
Drusen appear when sufficient material has been deposited, clin-
ically characterised by amorphous yellowish deposits beneath the
sensory retina. Four main types of drusen can be detected in the
retina. Hard drusen are discrete, yellow, nodular deposits, smaller
than 50 µm in diameter. Basal laminar drusen are tiny, whitish,
multiple deposits with a ’starry night’ appearance. Soft drusen are
yellowish deposits with poorly defined margins, tending to coa-
lesce, and are usually larger than 50 µm. Crystalline drusen are
discrete, calcific, refractile deposits. Drusen characteristics associ-
ated with a high risk of progression to exudative AMD (high-risk
drusen) include: soft drusen, more than five, larger size (greater
than 63 µm), drusen confluence and associated hyperpigmenta-
tion.
The cumulative incidence of new exudative or atrophic lesions in
eyes initially free of advanced AMD has been estimated as 8.6%
at one year, 16.4% at two years and 23.5% at three years (Holz
1994). Focusing on the CNV incidence, the results of a prospec-
tive investigation of people with exudative manifestation in one
eye and drusen in the fellow eye has shown that the risk of de-
veloping CNV peaks at four years, dissipating thereafter, whereas
there is a slightly increased incidence of geographic atrophy in the
longer term (Sarraf 1999). Moreover, the five-year risk of CNV
occurrence in the fellow eye of people who have already experi-
enced CNV in the first eye, varies from 7% to 87% depending
on the co-existence of four main risk factors (presence of five or
more drusen, focal hyperpigmentation, one or more large drusen
and systemic hypertension) (MPSG 1997).
Drusen can spontaneously disappear in people with AMD, gen-
erally leaving atrophic lesions. More specifically, the Waterman
study has reported that disappearance of large drusen occurred
in 16/47 (34%) participants in one five-year longitudinal study
(Bressler 1995).
Description of the intervention
Laser treatment is based on the release of a powerful beam of light
that, combined with ophthalmic equipment and lenses, can be
precisely focused on the retina to treat some diseases. The laser
energy causes a certain amount of controlled damage to the tissues
in order to obtain the desired effect. Small laser burns are usually
employed to obliterate or destroy abnormal blood vessels or other
lesions in the eye.
Several observers noted that laser application can lead to drusen
being resorbed in the macular area (Cleasby 1979; Gass 1973;
Gross-Jendroska 1998; Wetzig 1994). Owing to the risk of vision
loss associated with the presence of high-risk drusen, laser applica-
tion was proposed as an intervention to prevent progression to ad-
vanced AMD. Laser burns are applied to the retina, either directly
to the drusen or following pre-defined patterns. Argon, krypton,
dye or diode lasers have been used with varying levels of energy
(achieving from not visible to faint or intense whitish retinal le-
sions). The spot size used varies between 100 and 200 µm and
number of spots from less than 10 to nearly 300.
Subthreshold laser therapy is a more recent application of laser
energy to retinal diseases. The theoretical advantage of subthresh-
old laser is based on minimising the damage to the retinal tissue
by ensuring the energy spreads as little as possible. This aim can
be achieved by reducing the duration of laser exposure and oper-
ates with a sub-visible clinical endpoint. As a result, no laser scar
is produced in the retina, obtaining at the same time equivalent
clinical effects of conventional laser treatment (Sivaprasad 2010).
Several studies have shown that subthreshold laser photocoagula-
tion can be a viable option for several disorders, including diabetic
macular oedema (Lavinsky 2011; Luttrull 2012), macular oedema
secondary to branch retinal vein occlusion (Parodi 2006; Parodi
2008), and macular drusen. Subthreshold photocoagulation en-
compasses a range of techniques, among which micropulse sub-
threshold photocoagulation delivers light energy with very short
impulses that are absorbed by the RPE only, aiming to spare the
neurosensory retina.
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How the intervention might work
The mechanisms of laser-induced drusen regression are only spec-
ulative. Laser treatment may lead to an increased clearance of de-
bris by choroidal phagocytic cells or macrophages. Alternatively,
laser application may improve egress of drusen material through
a thinner or more permeable Bruch’s membrane, with the conse-
quent reduction of its outflow resistance. Laser effect may man-
ifest by triggering retinal pigment epithelial proliferation leading
to the production and release of cytokines and growth factors.
These molecules may be able to modify the biochemical process
underlying the clinicalmanifestations of the retinal disorder, rather
than simply destroying drusen, and may also act on the drusen
remote from the site of the laser energy application (Abdelsalam
1999; Frennesson 1998; Pauleikhoff 1990a; Pauleikhoff 1990b).
Histopathological examinations in animal models have shown
that phagocytic cells, probably derived from choriocapillaris peri-
cytes, can remove drusenoid material after laser photocoagulation
(Duvall 1985). Protrusion of choroidal endothelial cell processes
into Bruch’s membrane are enhanced by laser photocoagulation
and may play a part in the clearance of debris from the Bruch’s
membrane (Guymer 2001).
Micropulse laser delivery tries to achieve photostimulation rather
than photocoagulation (Luttrull 2012). However, the mechanism
of photocoagulation itself is poorly known, as reported above, thus
we also include micropulse photocoagulation in this review. Pi-
cosecond laser treatment has been attempted to achieve drusen
reduction and prevent CNV, a treatment that was defined “retinal
rejuvenation therapy (2RT)” (Guymer 2014). Using very short
laser pulses (3 ns), an insult caused by steam production around
melanosomes can be confined to the RPE inducing a highly se-
lective and discrete non-thermal injury. It has been hypothesised
that a 3-ns laser could induce migration of RPE cells and release of
matrix metalloproteinases, improving the hydraulic conductivity
of Bruch’s membrane. The hope is to achieve a prophylactic treat-
ment of early AMD without the potential harmful effects seen
with traditional thermal lasers.
Why it is important to do this review
AMD is a major public health problem in developed economies
where the life expectancy is greatest (but of no significance in
poorer countries with a life expectancy of under 65 years of age).
Several investigations about health-related and vision-targeted fea-
tures have shown that AMD is associated with decreased quality
of life (Brown 2006; Chakravarthy 2005; Hassell 2006; Maguire
2004; Mangione 1999).
Although people with drusen experience few visual symptoms,
once advanced AMD is present, visual loss is generally irreversible.
It has been shown that people with drusen who take antioxidant
supplementation are less likely to lose 15 or more letters of visual
acuity over the follow-up (AREDS 2001), even though this benefit
was considered modest in people with moderate to severe signs of
the disease (Evans 2012). Antioxidants have not been shown ben-
eficial in the primary prevention of AMD (Chong 2007). Thus,
the identification of a prophylactic treatment able to reduce the
complications related to AMD may be highly beneficial.
Laser treatment of drusen appeared to provide positive results in
observational studies (Cleasby 1979; Gass 1973; Gross-Jendroska
1998; Sigelman 1991; Wetzig 1994). A systematic review is neces-
sary to ensure that all the evidence on this intervention is consid-
ered objectively. People with AMD and their carers need to have
recommendations as to the possible benefits or harms of this in-
tervention.
O B J E C T I V E S
To examine the effectiveness and adverse effects of laser photoco-
agulation of drusen in AMD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials (RCTs) of laser
treatment of drusen in AMD.
Types of participants
People with retinal drusen associated with AMD in one or both
eyes.
Types of interventions
We included trials in which laser treatment for retinal drusen was
compared with no intervention or sham treatment. We consid-
ered a variety of different laser sources and photocoagulation tech-
niques.
Types of outcome measures
Primary outcomes
• Progression of AMD as measured by the development of
CNV.
• Progression of AMD as measured by the development of
geographic atrophy.
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Secondary outcomes
• Loss of visual acuity (LogMAR (logarithm of the Minimum
Angle of Resolution) values);
• Changes in contrast sensitivity;
• Drusen reduction;
• Changes in reading ability;
• Vision-related quality of life.
Visual acuity is generally measured using a standard chart, the
ETDRS (Early Treatment of Diabetic Retinopathy Study) chart
and scored in letters. There are five letters per line in this chart.We
extracted both dichotomous outcomes, such as moderate (3 lines
or 15 ETDRS letters) and severe (6 lines or 30 ETDRS letters)
visual loss and continuous measures (mean visual acuity) when
possible. Whenever no ETDRS values were used, we converted
visual acuity to LogMAR for pooling data.
Contrast sensitivity is generally measured with the Pelli-Robson
chart. Scores are collected in letters or as logarithm of contrast sen-
sitivity. We used the logarithm of contrast sensitivity for pooling
data when feasible. We extracted both continuous and dichoto-
mous measures if possible. For dichotomous data, we recorded
the proportion of participants with a change of at least 0.3 (cor-
responding to a two-fold change) or 0.6 log-units (corresponding
to a four-fold change).
In the protocol, we planned to evaluate drusen reduction con-
sidering the number of eyes showing at least a 50% reduction of
drusen area from the baseline aspect. However, data were sparsely
reported and, therefore, we modified the protocol to allow an ex-
traction based on the investigators’ definition.
We converted reading ability measures to LogMAR for reading
acuity, whereas we considered reading speed as the logarithm of
the number of words read in one minute.
Timing of outcome assessment
We assessed outcomes at 24 months, where data were available.
Adverse effects
We recorded adverse effects as documented in the included trials
but noted that themain complication of laser was visual loss, espe-
cially due to CNV, which is considered under Primary outcomes
and Secondary outcomes.
Microperimetry could be used to measure retinal sensitivity in
laser-treated perimacular areas in future studies, especially if the
aim is to document the presumed absence of damage expectedwith
subthreshold micropulse or nanosecond laser treatment. Thus, we
will extract such measure if available in future updates.
Search methods for identification of studies
Electronic searches
We searched CENTRAL (which contains the Cochrane Eyes
and Vision Group Trials Register) (2015, Issue 7), Ovid MED-
LINE, Ovid MEDLINE In-Process and Other Non-Indexed Ci-
tations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (Jan-
uary 1946 to August 2015), EMBASE (January 1980 to August
2015), Latin American and Caribbean Health Sciences Litera-
ture Database (LILACS) (January 1982 to August 2015), the IS-
RCTN registry (www.isrctn.com/editAdvancedSearch), Clinical-
Trials.gov (www.clinicaltrials.gov) and the World Health Orga-
nization (WHO) International Clinical Trials Registry Platform
(ICTRP) (www.who.int/ictrp/search/en).We did not use any date
or language restrictions in the electronic searches for trials. We last
searched the electronic databases on 3 August 2015.
See: Appendices for details of search strategies for CENTRAL (
Appendix 1),MEDLINE (Appendix 2), EMBASE (Appendix 3),
LILACS (Appendix 4), ISRCTN(Appendix 5),ClinicalTrials.gov
(Appendix 6), and the ICTRP (Appendix 7).
Searching other resources
We searched the reference lists of retrieved articles for details of
further relevant studies. We did not handsearch journals or con-
ference proceedings specifically for this review.
Data collection and analysis
Selection of studies
Two review authors independently assessed the titles and abstracts
resulting from the electronic searches for inclusion. We obtained
copies of all relevant or potentially relevant trials and assessed these
according to the Criteria for considering studies for this review.
The review authors were notmasked as to the names of authors, in-
stitutions, journal of publication or results when making their as-
sessments.We resolved disagreements about whether a trial should
be included by discussion and consensus. In cases where additional
information was needed before a decision was made whether to
include a trial, we obtained this information by contacting the
authors.
Data extraction and management
We recorded information about the methods used in the trial on a
form including details of participants, details of intervention, out-
comes and other information. Two review authors independently
extracted the data for the primary outcomes, secondary outcomes
and adverse effects onto paper forms. Since the double-entry facil-
ity is no longer available in Review Manager 5, one review author
extracted data and entered them into Review Manager 5 for the
update (RevMan 2014), and another review author checked the
entries for errors and inconsistencies.
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Assessment of risk of bias in included studies
Two review authors independently assessed the included trials
for bias according to the methods described in Chapter 8 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011a). With the update of review management software, we as-
sessed risk of bias using the tool set out in Higgins 2011a.
• Sequence generation: the method used to generate the
allocation sequence, to assess whether it should have produced
comparable groups.
• Allocation concealment: the method used to conceal the
allocation sequence, to determine whether intervention
allocations could have been foreseen in advance of, or during,
enrolment.
• Masking of personnel and outcome assessors: the
assessments were made for each main class of outcomes (i.e.
anatomic versus functional outcomes) and we considered
whether all measures used, if any, to mask study personnel from
knowledge of which intervention a participant received were
adequate.
• Incomplete outcome data: the assessments were made for
each main class of outcomes (i.e. anatomic versus functional
outcomes) when possible and were based on the description of
the completeness of outcome data, including attrition and
exclusions from the analysis and their causes, if they were
reported.
• Selective outcome reporting: the possibility of selective
outcome reporting, such as found when some measures were
obtained, as declared in the methods section or in protocols, but
not reported in the results section.
We used the following grading:
• low risk of bias: plausible bias unlikely to seriously alter the
results;
• unclear risk of bias: plausible bias that raises some doubt
about the results;
• high risk of bias: plausible bias that seriously weakens
confidence in the results.
If the information available in the published trial reports was in-
adequate to assess any of the above items of the risk of bias as-
sessment, we contacted the trial authors for clarification. If they
did not respond within a reasonable period, we classified the trial
based on the available information. When studies did not report
any concealment approach, we considered adequacy unclear. We
also assessed the impact of any assumptions made in this regard in
a sensitivity analysis.
We considered a trial to have conducted an intention-to-treat anal-
ysis only if it included all participants who were randomised in-
cluding those randomised but not treated and excluded after ran-
domisation for other reasons.
Measures of treatment effect
We evaluated development of CNV and geographic atrophy on
the basis of the percentage of their occurrence over the follow-up.
We assessed visual acuity loss taking into consideration the loss of
3 or more lines of visual acuity, which corresponds to a doubling
of the visual angle if visual acuity is measured using a logMAR
chart.
We planned to evaluate drusen reduction considering the number
of eyes showing at least a 50% reduction of drusen area from
the baseline aspect. However, data were sparsely reported and,
therefore, we modified the protocol to allow an extraction based
on the investigators’ definition.
Dichotomous data
Dichotomous data included, for example, progression of CNV or
geographic atrophy, or loss of 3 ormore lines of visual acuity. In the
protocol, we stated that we would have used the risk ratio (RR) as
our preferred measure of effect since we anticipated that the event
rate would be greater than 10%. We actually found that the event
rate was lower than this threshold in bilateral studies. Furthermore,
to be able to manage data from unilateral and bilateral studies,
we had to manipulate them using formulas proposed by Elbourne
2002, which only apply to odds ratios (OR). Little difference is
expected between RRs and ORs in this review, since the crude
event rate was less than 10% in bilateral studies and less than 25%
in unilateral studies, and also because the pooled OR was close to
1.
Continuous data
Continuous data included, for example, reading speed. We used
the mean difference (MD), unless the outcomes were measured
on different scales in which case we used the standardised mean
difference as the measure of effect.
Unit of analysis issues
Some trials identified a ’study eye’ and randomised participants
to treatment group. Other trials randomised the eye to treatment
and compared it with the other eye in the same person. We were
careful to consider these trials separately at the data collection and
extraction stage.
We did two sets of analyses for the primary outcome ’development
of CNV’. First, we pooled all the data ignoring the fact that the
data from the bilateral studies were not independent. Second, we
then did a sensitivity analysis assuming an intra-class correlation
coefficient (ICC) of 0.5 for the development of CNV and 0.22 for
visual acuity loss. We adjusted the standard errors using the meth-
ods given in Chapter 16 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011b) and Elbourne 2002. See
Appendix 7 for more details on the method used.
We used the generic inverse variance facility in Review Manager
5 to enter the data for the sensitivity analysis (RevMan 2014).
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Dealing with missing data
In the event that data were missing, we contacted the authors of
the studies in an attempt to obtain more information. On the
basis of the data we could collect, we first did an available case
analysis. We recorded the amount of missing data in the included
studies as shown in Table 1. At the time the protocol for this review
was prepared, we planned that if missing data should prove to be
a problem in the constituent studies, we would consider doing
a sensitivity analysis considering outcome in the people lost to
follow-up as either ’all OK’ or ’all not OK’ to see the range within
which the true result might lie. This did not prove necessary at
this stage. According to further guidance available in Chapter 8
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011a), missing outcome data are not a problem if loss to
follow-up is both balanced in the study arms of parallel arm studies
and causes of loss are documented and judged to be unrelated
to outcome in both study arms. When these conditions are not
satisfied, a study can still be at low risk of bias if the outcome
frequency is about 50% and loss to follow-up is below 10% in
both arms (Higgins 2011a).
Because our primary outcomes were relatively rare in the com-
plete case analysis in this review, and there were missing data of
unreported cause, there was potential for bias due to incomplete
outcome data in this review. In the updated version of this review,
we considered missing data as at no risk of bias in bilateral studies
because a participant with paired treatment and control eyes is
missed. For each unilateral study, we assessed the risk of bias us-
ing methods described in Appendix 8, based on the users’ written
function ’metamiss’ in Stata 13.1 (StataCorp 2013) to conduct
sensitivity analyses on primary outcome meta-analysis results by
making different assumptions on informative missingness odds
ratios (IMORs) across studies according to White 2008.
Finally, in the updated version of this review, we used the user
written command extfunnel in Stata to assess the impact of a new
study on the meta-analysis according to Langan 2012.
Assessment of heterogeneity
Before carrying out a meta-analysis, we assessed heterogeneity by
examining the characteristics of the study, the forest plot of the
results of the studies and the I2 statistic to assess the presence of
statistical heterogeneity.
Assessment of reporting biases
We investigated small-study bias using contour enhanced funnel
plot (Peters 2008), and assessed significance of funnel asymmetry
using Harbord’s test (Harbord 2006).
Data synthesis
Weplanned toperformameta-analysis if therewere sufficient trials
available without substantial heterogeneity. We used a random-
effectsmodel unless therewere three or fewer trials inwhich casewe
used a fixed-effect model. We compared fixed-effect and random-
effects models to see how robust the results were.
Subgroup analysis and investigation of heterogeneity
We conducted the following subgroup analyses for the primary
outcome ’development of CNV’:
• type of laser treatment, mainly laser wavelength;
• clinically visible burns versus sub-threshold laser treatment.
Studies were duplicated when there were three arms and two dif-
ferent laser wavelengths were compared, and study arms were col-
lapsed when unilateral and bilateral studies were published simul-
taneously.
Sensitivity analysis
We considered the results of between-person and within-person
trials separately.We had planned to consider the effect of excluding
poor quality studies, if there were sufficient studies. This was not
done.
Themethods for this reviewwere published in the protocol (Parodi
2007).
Summary of findings
We prepared Summary of findings for the main comparison as per
guidance given in Chapter 11 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Schünemann 2011), and graded
the overall quality of the evidence for each outcome usingGRADE
(GRADEpro 2015).
R E S U L T S
Description of studies
Results of the search
The original searches identified 111 reports of studies. We ex-
cluded Sarks 1999 and Sigelman 1991 because the treatment
groups were not randomly allocated. Overall, nine trials were con-
sidered suitable for inclusion in the review of which two included
both a unilateral and a bilateral arm with data available for both
(DLS; Olk 1999), and four were only bilateral (CAPT; Figueroa
1994; Little 1995; PTAMD bilateral 2009). One study was pub-
lished in abstract form only and the investigators supplied unpub-
lished data for inclusion in this review (Laser to Drusen Study
1995).
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An update search run in August 2015 identified a further 174
references (Figure 1). The Trials Search Co-ordinator removed 60
duplicates and screened the remaining 114 references, of which
59 were not relevant to the scope of the review. We reviewed the
remaining 55 references and discarded 49 reports as not relevant.
We obtained six full-text reports for potential inclusion in the
review and included two new studies in the review (Frennesson
2009; PTAMD bilateral 2009). We excluded studies by Huang
2011 and Guymer 2014, see Characteristics of excluded studies
table for reasons. We also added two ongoing studies, Beaumont
2011 and NCT01790802. Beaumont 2011 was only published
as an abstract and the authors confirmed results still had to be
published. NCT01790802 aimed to treat 250 participants with
nanosecond laser treatment, starting in November 2011 with es-
timated study completion in June 2017.
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Figure 1. Study flow diagram.
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Included studies
See Characteristics of included studies table.
Types of studies
The study design was different across studies. Four studies in-
cluded one eye of each participant (Frennesson 1995; Frennesson
2009; Laser to Drusen Study 1995; PTAMD unilateral 2002),
and we refer to them as ’unilateral’ studies. Four studies adopted a
paired design whereby both eyes of the participant were included
in the study, one eye randomly allocated to photocoagulation or
control and the fellow eye to the other group (CAPT; Figueroa
1994; Little 1995; PTAMD bilateral 2009), and we refer to them
as ’bilateral’ studies. Three more studies included both a unilateral
and a bilateral arm (CNVPT;DLS;Olk 1999).However, CNVPT
did not report results from the bilateral study arm except for the
number of participants with a gain of 1 or more lines of visual
acuity at one year in an early report and, therefore, we could not
extract data on this arm.
Types of participants
The 11 trials randomised 3629 people. The studies took place
in the US (CAPT; CNVPT; Laser to Drusen Study 1995; Little
1995; Olk 1999; PTAMD bilateral 2009; PTAMD unilateral
2002), Sweden (Frennesson 1995; Frennesson 2009), Denmark
(Frennesson 2009), Finland (Frennesson 2009), the UK (DLS),
Germany (DLS), Australia (DLS), and Spain (Figueroa 1994).
The mean age of the participants was approximately 70 years. The
majority of participants were women in all studies (range 54% to
70%).
All studies recruited participants presenting medium (greater than
63 µm) or large (greater than 125 µm) drusen with pigmentary
changes. CNVPT,DLS, Figueroa 1994, and Frennesson 2009 en-
rolled participants with bilateral macular drusen in the bilateral
arm and participants with neovascular AMD in one eye and mac-
ular drusen in the fellow eye in a unilateral study. Little 1995,
Olk 1999, Frennesson 1995, PTAMD bilateral 2009, and CAPT
enrolled participants with macular drusen in both eyes.
Types of interventions
Table 2 gives details of the laser treatment employed in the dif-
ferent studies. Six studies employed argon laser, three diode laser
and two dye laser. Laser spot size varied from 50 to 200 µm. The
duration of each burn ranged from 0.05 seconds to 0.2 seconds.
The number of laser spots included was between one and 100.
PTAMD unilateral 2002 and PTAMD bilateral 2009 used sub-
threshold photocoagulation using an 810-nm diode laser in all
treated participants. Frennesson 2009 used subthreshold photo-
coagulation a using argon green laser. Olk 1999 used subthreshold
photocoagulation in a random subset of treated eyes. Subthresh-
old photocoagulation was obtained by lowering the power that
achieves standard photocoagulation and no study usedmicropulse
photocoagulation.
Primary outcomes
Six bilateral studies or study arms (CAPT; DLS; Figueroa 1994;
Little 1995; Olk 1999; PTAMD bilateral 2009), and seven
unilateral studies or study arms (CNVPT; DLS; Frennesson
1995; Frennesson 2009; Laser to Drusen Study 1995; Olk 1999;
PTAMD unilateral 2002) presented data on the outcome ’devel-
opment of CNV’.
We stated in the protocol that we aimed to obtain data at two years.
However, we used three-year data for three studies that reported
the outcome with more detail at this time point (DLS; Frennesson
1995; PTAMD bilateral 2009). For PTAMD bilateral 2009, the
number of events were calculated applying the percentage esti-
mated fromKaplan-Mayer survival curves to complete cases; Little
1995 and Frennesson 2009 used the last visit at a mean of 3.2
years (Little 1995) and 3.7 years (Frennesson 2009).
CAPT and Olk 1999 did not report crude data at two years, but
presented survival curves, fromwhich we extracted graphically the
proportion of people with CNV and atrophy at two years using
the number of eyes followed up in each group to compute standard
errors. Most bilateral studies provided marginal data only (i.e. a
frequency tabulation that ignores the paired nature of data), but
we could extract and use a correlation coefficient from DLS as
shown in Appendix 7.
Among bilateral studies, we could extract paired data on devel-
opment of CNV from Little 1995, but we considered that this
study was too small to estimate the correlation coefficient reliably.
CAPT provided marginal data, but the P value was obtained from
a Cox proportional hazards model, not from a McNemar Chi2
test; thus, we did not use the method shown in Appendix 7.
There was poor reporting of the primary outcome ’development of
geographic atrophy’. Data from Laser to Drusen Study 1995 were
obtained from the authors. Data from survival curves could be
estimated from the unilateral arm of CNVPT; cross-tabulations
were constructed using the number of complete cases who did not
develop CNV because, in the absence of a clear reporting of the
total number of eyes at each step of the survival curve, we consid-
ered that eyes with a neovascular lesion may have complex fundus
changes preventing a precise assessment of geographic atrophy.
Secondary outcomes
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Loss of visual acuity was the only secondary outcome that could
be extracted for most studies. Particularly, DLS, CAPT, Figueroa
1994, and PTAMD bilateral 2009 presented bilateral data and
DLS, Olk 1999, DLS, PTAMD unilateral 2002, and CNVPT
presented unilateral data. Most studies provided marginal data,
but we could extract a correlation coefficient from Little 1995
and DLS and use it as shown in Appendix 7 to obtain correct
standard errors. Frennesson 2009 only reportedmean visual acuity
and dichotomous data on visual loss could not be obtained.
Only CNVPT presented contrast sensitivity and reading ability
data.
Most studies analysed drusen reduction. It was possible to extract
data on this outcome from two unilateral studies and one bilateral
study. For CNVPT, we extracted data graphically from a survival
curve using the number of eyes followed up in each group to
generate a cross-tabulation of the eyes with a 50% or more drusen
area reduction among treated and control eyes. Two studies gave
the approximate percentages with apparent drusen reduction:
PTAMDunilateral 2002 at 18months andPTAMDbilateral 2009
at two years. We used the number of participants still followed
minus those who developed CNV as the total number in each
group for generating the 2 x 2 table. We could not extract data
on drusen reduction from the other studies. In fact, CAPT and
Little 1995 were bilateral studies but reported marginal data only.
Olk 1999 provided pooled data only for unilateral and bilateral
cases. Frennesson 1995 provided means and standard deviations
but used Snellen values to compute them, which is incorrect, and
data had a very skewed distribution. Thus, we decided not to use
data from this study. DLS did not report drusen reduction.
None of the studies reported quality of life data.
Other comparisons
Olk 1999 also compared subthreshold (i.e. yielding non-visible
laser burns) photocoagulationwith observation.Weobtainedmar-
ginal data from the bilateral study arm, but no estimate of the
intraindividual correlation, together with data from the unilateral
study arm.
Excluded studies
See Characteristics of excluded studies table.
We excluded four studies: Guymer 2014 was not an RCT, Huang
2011 as the investigator reported that treatment was randomised,
but then the participant could choose which eye would receive
laser treatment; Sarks 1999, which was a comparative but non-
randomised study and Sigelman 1991, which was a case report.
Sivagnanavel 2004 and Beaumont 2011 have only been published
as an abstract. In particular, Beaumont 2011 treated 121 partici-
pants with subthreshold photocoagulation and used the fellow eye
as control, finding that drusen disappeared and that there was a
small benefit of borderline significance on visual acuity; the con-
tact author reported treatment assignment to either eye was ran-
domised and the study was ongoing and unpublished. We are still
trying to contact Sivagnanavel 2004, but have not as yet received
further information and so have placed this study under Studies
awaiting classification.
Risk of bias in included studies
See ’Risk of bias’ tables in Characteristics of included studies table
and Figure 2.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Slightly more than half of the trials reported adequate methods to
generate and conceal the allocation sequence.
Blinding
Participants were not masked (blinded) since a sham procedure
was never adopted. We acknowledge that it is not possible to mask
outcome assessors to anatomic outcomes because laser scars are
visible around the macula, unless subthreshold photocoagulation
is used and effective. However, masking of functional outcome
assessors can be achieved in theory, but was rarely so, or reported
as such, in these studies. We think that development of CNV is a
sufficiently objective diagnosis to be classified as having low risk of
bias despite lack of masking of outcome assessors. On the contrary,
vision outcomes such as visual acuity and contrast sensitivity can
easily be measured by a masked assessor, and lack of masking can
introduce bias because the procedure is operator dependent.
Incomplete outcome data
Table 1 shows events and non-events of complete cases, number
of deaths and number of missing participants in the treatment and
control arms.We used these data to assess the impact of incomplete
outcome data only in unilateral studies. In fact, in the updated
version of this review, we considered missing data as at no risk of
bias in bilateral studies because a participant with paired treatment
and control eyes is missed.
Figure 3 shows the potential impact of missing data using the
method described in Appendix 8. Based on this analysis, only
PTAMD unilateral 2002 was at high risk of bias for missing data.
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Figure 3. Photocoagulation versus control, outcome: Development of CNV at two years (see ; CNVPT;
Laser to Drusen Study 1995; Olk 1999; PTAMD unilateral 2002). Graphical assessment of the risk of bias due
to incomplete outcome data in unilateral studies with missing data reported (see Appendix 8). The minimum
and maximum odds ratio change, compared to complete or available cases, is assessed graphically and
subjectively taking into account its 95% CI. CI: confidence interval; max: maximum; min: minimum.
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Frennesson 2009 was a unilateral study, but we could only obtain
the number of events at the end of follow-up (about 3.5 years) and
could not extract missing data at two years. Thus, we scored the
study at unclear risk of bias for incomplete outcome data.
Selective reporting
Most studies reported the development of CNV and visual acuity,
which are the key outcomes in this study, so selective reporting
was not a problem in this review.
Other potential sources of bias
One trial was stopped early because an interim analysis suggested
a harmful effect of photocoagulation (DLS).
The laser producers sponsored three out of four studies using
laser subthreshold photocoagulation (Olk 1999; PTAMDbilateral
2009; PTAMD unilateral 2002).
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings table: photocoagulation of drusen versus control
Primary outcomes
Development of choroidal neovascularisation
Pooling the results, as seen in Figure 4, showed that photocoagula-
tion did not reduce the development of CNV at two years’ follow-
up (OR 1.07, 95% CI 0.79 to 1.46, 11 studies, 2159 participants
(3580 eyes), high quality evidence; Analysis 1.1). This estimate
means that, given an overall occurrence of CNV of 8.3% in the
control group, we estimated an absolute risk reduction of no more
than 1.4% in the laser group, which is sufficient to exclude a bene-
fit, or an increase of more than 2.8%, which is sufficient to exclude
an important harm in this low risk population.
Figure 4. Forest plot of comparison: 1 Photocoagulation versus control, outcome: 1.1 Development of
choroidal neovascularisation (two studies provided data on both unilateral and bilateral participants).
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A sensitivity analysis assuming moderate correlation (0.5) of the
outcomewithin individuals increased the heterogeneity of bilateral
studies to an I2 value of 52%, but Analysis 1.2 shows that the
conclusions would not change.
Figure 5 presents a graphical exploration of small-study bias in
a contour-enhanced funnel plot. In this analysis, we pooled data
from bilateral and unilateral studies when they were based on a
similar protocol and published simultaneously. Although there
were two small studies in the area of larger effect, the lower-left
corner of the plot, the Harbord test did not suggest statistical
significance of funnel plot asymmetry (P value = 0.444).
Figure 5. Contour enhanced funnel-plot investigating small study bias for the primary outcome
’development of choroidal neovascularisation or geographic atrophy’. Shaded areas are areas of statistical
significance as explained in the legend.
Development of geographic atrophy
We could extract data on the development of atrophy from only
two small studies (CNVPT; Laser to Drusen Study 1995). Anal-
ysis demonstrated no benefit or harm using photocoagulation for
development of geographic atrophy (OR 1.30, 95% CI 0.38 to
4.51; Analysis 1.3). The quality of the evidence was low because
of imprecision.
One bilateral study presentedmarginal data on development of ge-
ographic atrophy. Specifically,CAPT reported that 1.9%of treated
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eyes compared to 1.4% of control eyes of 1008 participants devel-
oped atrophy at two years, but due to the paired nature, we could
not extract and analyse these data.
Secondary outcomes
Visual acuity
Four bilateral studies and five unilateral studies allowed the ex-
traction of data on the risk of visual loss of 3 or more lines of
visual acuity at two years (a value of 2 or more lines was avail-
able in Olk 1999 and PTAMD bilateral 2009) (Analysis 1.4). The
analysis demonstrated no benefit or harm with photocoagulation
(OR 0.99, 95% CI 0.81 to 1.22). The quality of this evidence
was moderate because visual acuity examiners were masked in less
than half of studies.
Contrast sensitivity
We obtained data on contrast threshold from the authors of Laser
to Drusen Study 1995. There was a large uncertainty of the es-
timates (low quality evidence; Analysis 1.5) and analysis demon-
strated no effect of photocoagulation.
CAPT also reported on contrast sensitivity, but this was a paired
study and the data could not be analysed since an estimate of
the correlation coefficient was not obtained. The authors reported
marginal data at five years, which indicated that 212/888 (23.9%)
treated eyes and 182/887 (20.5%) observed eyes required twice as
much contrast (corresponding to a loss of 0.3 log 10 units or more
of contrast sensitivity) to read letters.
Reading ability
We obtained data on reading speed from the authors of Laser to
Drusen Study 1995 for about 50% of the participants included
in this small study. Analysis found no statistically significant dif-
ference between photocoagulation and observation (low quality
evidence due to imprecision; Analysis 1.6).
CAPT also reported marginal data on reading ability expressed
as critical print size (i.e. the character print’s size below which a
person’s reading speed slows down).The authors reportedmarginal
data at five years, which indicated that 260/879 (29.6%) treated
eyes and 249/878 (28.4%) observed eyes required a print size twice
as large (0.3 LogMAR or 3 lines) or could not read even the largest
print size.
Drusen reduction
We extracted data on drusen reduction as defined by the investi-
gators from two unilateral studies (CNVPT; PTAMD unilateral
2002), and one bilateral study (PTAMD bilateral 2009), at ap-
proximately two years (Analysis 1.7). All three studies found an
apparent drusen reduction in treated eyes compared to control
eyes with a cumulative OR of 9.16 (95% CI 6.28 to 13.37, 944
eyes, high quality evidence).
Among bilateral studies, others presentedmarginal data suggesting
that photocoagulation caused drusen resorption, but we could not
extract these data since an estimate of thewithin-person correlation
was not obtained. Specifically, CAPT found that 34.3% of treated
eyes versus 8.6% of control eyes of 1008 participants had a 50%
drusen reduction at two years. Figueroa 1994 reported that 29/
30 treated eyes versus 2/30 control eyes had drusen reduction,
on average after three months. Little 1995 reported that 17/27
treated eyes had drusen resorption by six months compared to 5/
27 observed eyes by one year.
Other studies reported data suggesting drusen disappearance using
photocoagulation compared to observation, but we could not ex-
tract data for various reasons (means and standard deviations sug-
gesting skewed data (Frennesson 1995; Frennesson 2009), pooled
data from unilateral and bilateral study arms (Olk 1999), or data
not available (DLS)).
Quality of life
None of the studies reported quality of life.
Subgroup analysis
We conducted subgroup analyses for the primary outcomes only
(development of CNV and geographic atrophy).
Type of laser
We conducted a subgroup analysis comparing argon, diode and
dye laser, pooling data from unilateral and bilateral studies when
they had been conducted and reported simultaneously using sim-
ilar methods. We excluded DLS since it used two types of laser
and no separate data were available.
Although there was some subgroup heterogeneity (I2 = 53%), the
P value for subgroup differences did not reach significance (P value
= 0.12), and none of the groups showed a significant increase or
decrease of the risk of CNV (Analysis 1.8).
Visible versus subthreshold photocoagulation
In the update of this review, we included two more studies adopt-
ing subthreshold photocoagulation (Frennesson 2009; PTAMD
bilateral 2009). Thus, we could conduct a subgroup analysis com-
paring visible, standard photocoagulation (eight studies, 2870
eyes) with subthreshold photocoagulation (four studies, 950 eyes)
(Analysis 1.9). We could not show statistically significant differ-
ences between the two groups (I2 = 9%, P value = 0.29) and the
OR in the subthreshold group excluded a large benefit (OR 1.27,
95% CI 0.82 to 1.98).
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Adverse effects
We considered adverse effects such as development of CNV, de-
velopment of geographic atrophy and visual loss above.
Only one trial formally considered additional adverse effects. They
noted that, “There were no reports of burns applied to the foveal
avascular zone, breaks in Bruch’s membrane, or haemorrhages at
the initial or 1-year treatment” (CAPT).
Olk 1999 noted a juxtafoveal scar in one eye (out of 63 eyes)
treated with visible burns.
Potential impact of a new study
As explained in the Data synthesis section, we assessed the po-
tential impact of a new study on the meta-analysis according to
Langan 2012. Figure 6 shows that it is unlikely that further re-
search will change the results of this review, since they should be
either favourable studies and much larger than those included, or
smaller but with favourable effects far exceeding those observed
in this review. This is compatible with the fact that no trials were
published after 2009.
Figure 6. Potential impact of a new study on the meta-analysis using the command ’extfunnel’ in Stata (see
Data synthesis and Langan 2012). sig: significant.
D I S C U S S I O N
AMD is a disease characterised by an enormous social burden. The
availability of a therapeutic approach able to reduce the incidence
of the major complications (i.e. CNV and atrophy) would be
extremely welcome. Several authors have recorded that in their
experience the use of laser can result in reabsorption of macular
drusen (Cleasby 1979; Figueroa 1994; Gass 1973; Wetzig 1994).
As yet, it is unclear whether drusen reduction can lead to clinical
benefits, including improvement or stabilisation of visual acuity,
delayed or reduced CNV, or harms such as the onset of atrophy.
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Summary of main results
In the update of this review, we identified two new trials, leading
the total number to 11 studies, in which 2159 participants (3580
eyes) were randomised to laser treatment of drusen or observation
and followed up to at least two years. These trials confirmed the
clinical observation that laser photocoagulation of drusen was able
to cause their disappearance. However, there was no evidence that
this loss of drusen resulted in any benefit in terms of the devel-
opment of CNV or geographic atrophy or prevention of visual
acuity loss. The results of the present review indicated that the
prophylactic laser treatment of drusen is ineffective as a means for
delaying the progression of AMD and preventing visual loss. A
clinically relevant benefit can be excluded for people at medium
risk of CNV, which was about 9% within two years in our pri-
mary meta-analysis, based on the primary outcomes. Among the
secondary outcomes, the CI of the visual loss outcome also tended
to exclude important harms.
The two new studies used near-infrared subthreshold photocoag-
ulation, totalling four studies with 539 eyes of different people
treated with this technique. The meta-analytic OR and its 95%
CI also did not suggest potential for benefit. However, no study
included in this review used micropulse subthreshold photoco-
agulation, since photocoagulation was used with low power but
continuous laser light delivery.
Overall completeness and applicability of
evidence
Some of these trials adopted a paired study design (six studies, 1454
participants), which rendered the analysis of the data difficult.
Moreover, only a few studies reported data on secondary outcomes,
especially contrast sensitivity and reading ability. Despite these
limitations, the studies included in this review were conducted in
different countries and follow-up length was enough to be able to
record long-term effects of this intervention.
Quality of the evidence
Overall, we judged the evidence included for the primary outcome
’development of CNV’ represent high quality of evidence (i.e. that
we are reasonably certain that the estimate of effect represents the
true value). We downgraded the judgement of quality to low for
the other primary outcome ’development of geographic atrophy’
because there were only two studies with few participants and,
therefore, the effect estimates were very imprecise.
Potential biases in the review process
One source of bias in this review may be the pooling of unilateral
and bilateral studies based on assumptions about the statistical
correlation of within-person data. To try to counteract this po-
tential shortcoming, we not only used the information available
from some studies, suggesting very low correlation for the primary
outcome ’occurrence of CNV’, but also used a mean correlation
as a sensitivity analysis, which did not change the conclusions of
our review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Even though drusen area reduction can be achieved through laser
treatment, this review suggests that this intervention is not asso-
ciated with improved outcomes for the patients, based on meta-
analyses of studies, which, overall, had a low risk of bias.
Implications for research
The results of this review suggest there is no need to conduct more
research on photocoagulation directed to drusen in people with
AMD, in accordance with the fact that no further trials were pub-
lished after 2009. We acknowledge that the evidence on different
lasers sources and strategies, such as the subthreshold one, is more
limited, yet our findings do not seem to differ for this subtype of
laser photocoagulation, if it is obtained with low-power continu-
ous laser light, such as in the included studies, which did not use
micropulse photocoagulation.
A study is ongoing to investigate the effect of nanosecond laser
treatment to drusen.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
CAPT
Methods Method of allocation: treatment assignments were generated using a randomly permuted
block method, stratified by clinical centre and using a randomly chosen block size. A
member of the CAPT Co-ordinating Centre reviewed an eligibility checklist with the
local ophthalmologist and clinic co-ordinator during a teleconference before disclosing
which of the 2 eyes was assigned to laser treatment
Masking: masked VA examiners. Unclear if participants and care providers were masked.
Not reported if anatomic outcomes assessors were masked (i.e. Photograph Reading
Centre), butmaskingwas unlikely to be achieved since photocoagulation generates visible
scars
Exclusions after randomisation: none reported
Losses to follow-up: during 5 years of follow-up, 5891 (97.2%) visits were completed of
the 6061 6-month and annual visits scheduled for surviving CAPT participants. This
percentage was relatively stable over time
Unusual study design: bilateral or paired study, i.e. 1 eye randomised to treatment or
control and the fellow eye to the other study arm
Participants Country: US
Number randomised: 1052 participants
Enrolment period: May 1999 to March 2001
Age: mean 71 years
Sex: 637 women (60.6%)
Inclusion criteria: at least 10 drusen of size ≥ 125 µm within 3000 µm of FAZ centre;
BCVA: 20/40 or more; aged ≥ 50 years
Exclusion criteria: CNV or serous retinal PED in either eyes; geographic atrophy within
500 µm of FAZ centre; any ocular disease that might affect VA
Interventions Treatment: 60 burns in a grid pattern using a 100-µm spot size, 0.1-second duration
and power to achieve a barely visible lesion. The burns were applied within an annulus
between 1500 and 2500 µm from the FAZ centre
Control: observation
Outcomes Primary: loss of ≥ 15 letters
Secondary: change in VA; change in contrast sensitivity; change in critical print size;
incidence of late AMD (CNV, serous PED, geographic atrophy)
Notes Since 2001, the participants were informed of the AREDS results and were left free to
consume antioxidants
Supported by the National Eye Institute, Bethesda, Maryland (grant nos: EY012211,
EY012261, EY012279)
COI declaration: the Manuscript Writing Team had no COI with regard to the material
presented in the article
Risk of bias
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CAPT (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly permuted block method used,
stratified by clinical centre and using a ran-
domly chosen block size
Allocation concealment (selection bias) Low risk Eligibility assessed before randomisation
and central allocation by telephone
Blinding (performance bias and detection
bias)
Development of CNV/geographic atrophy
Low risk Unmasked study, but CNV occurrence was
sufficiently objective as a diagnosis to be
considered unbiased
Blinding (performance bias and detection
bias)
Measurement of vision
Low risk Masked VA examiners, unclear if care
providers were masked. Participants could
not be masked since no sham procedure
was mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk See Appendix 8. Throughout 5 years of
follow-up, 5891 (97.2%) visits were com-
pleted of the 6061 6-month and annual vis-
its scheduled for surviving CAPT partici-
pants. This percentage was relatively stable
over time. In the updated version of this re-
view, we considered missing data as no risk
of bias in bilateral studies because a par-
ticipant with paired treatment and control
eyes is missed
Selective reporting (reporting bias) Low risk Development of CNV and atrophy, as well
as loss of ≥ 3 lines of VA were well defined
and relevant outcomes
Other bias Unclear risk Unclear
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CNVPT
Methods BILATERAL: method of allocation: right eye randomly assigned to either laser treatment
or observation. Left eye assigned to alternate treatment
UNILATERAL: random allocation to laser treatment or observation
Stratified by clinical centre and study (bilateral/unilateral) and blocked using a randomly
selected block size. Issued over telephone from central location
Masking: participant: no; provider: unclear; outcome: no for fundus features; yes for VA
Exclusions after randomisation: not reported
Losses to follow-up: among participants alive at 12 months, 57/57 were examined in
the laser group and 58/61 in the observation group. At 2 years, 46/57 (80.7%) treated
eyes compared to 47/58 (81%) control eyes were still followed. However, causes of loss
to follow-up other than death were not reported
Participants Country: US in 15 clinical centres
Enrolment period: October 1994 to December 1996
BILATERAL: number randomised: 156 participants (312 eyes). Age: mean 71 years.
Sex: 61% women
UNILATERAL: number randomised: 120 participants. Age: mean 73 years. Sex: 63%
women in treatment group; 59% women in control group
Inclusion criteria: aged ≥ 50 years with colour stereo photographs and a fluorescein
angiogram of both eyes taken within 14 days of enrolment, free of any condition that
would preclude 2 years’ follow-up. No exudative AMD. Study eye: > 10 large drusen (>
63 µm) within 3000 µm of the FAZ with VA of 20/40 or better and no evidence of
current or past CNV
BILATERAL: no exudative AMD in both eyes
UNILATERAL: no evidence of current or past CNV. Exudative AMD in fellow (non-
study) eye
Exclusion criteria: evidence of serous PED≥ 1MPS disc area, geographic atrophy within
500 µm of the centre of the FAZ, myopia (≥ 8 dioptres spherical equivalent), previous
laser treatment to the retina, severe non-proliferative or proliferative diabetic retinopathy
or diabetic macular oedema, progressive ocular disease
Interventions Treatment: low-intensity laser treatment. 3 different laser treatment protocols: 1. Laser
20: 20 laser burns, 100 µm in diameter, in a pattern of 3 rows placed between the 12
and 6 o’clock positions beyond the temporal perimeter of the FAZ. The desired intensity
of the burns was a grey-white lesion. Direct application of laser burns to drusen to be
avoided. Whenever the area of drusen had not been reduced by ≥ 50% at 6 months of
enrolment, a second treatment was applied nasal to the fovea in a mirror image of the
first treatment. During the last 6 months of enrolment, a second laser treatment protocol
was adopted that specified 24 laser burns, 100 µm in diameter in a circular pattern of 2
rows surrounding the macular drusen
Control: observation of fellow eyes
Outcomes VA (EDTRS); contrast threshold (Pelli Robson); reading ability (MN Read charts)
Development of CNV, development of geographic atrophy, disappearance of drusen
(stereoscopic colour photographs of the macular and disc of each eye and fluorescein
angiogram)
Notes Enrolment in these pilot studies was suspended after recommendation by the Data
and Safety Monitoring Committee (DSMC) because there was a higher incidence of
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CNVPT (Continued)
CNV within 12 months of study enrolment in laser-treated eyes than in observed eyes,
predominantly in the Fellow Eye Study
Furthermore, data from the bilateral study arm were reported at 12 months but not
thereafter
Supported by an unrestricted gift from Research to Prevent Blindness, New York, NY,
to the University of Pennsylvania; gifts to the Macular Degeneration Research Fund,
Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA; grants
from the Macula Foundation, New York, NY; Research Foundation of the University
of Pennsylvania, Philadelphia, PA; and Mackall Trust, New York, NY; and grant R21
EY11275 from the National Eye Institute, National Institutes of Health, Bethesda, MD
COI declaration: none of the authors have a proprietary interest in this study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified by clinical centre and study (bi-
lateral/unilateral) and blocked using a ran-
domly selected block size
Allocation concealment (selection bias) Low risk Issued over the telephone from central lo-
cation
Blinding (performance bias and detection
bias)
Development of CNV/geographic atrophy
Low risk Unmasked study, but CNV occurrence was
sufficiently objective as a diagnosis to be
considered unbiased
Blinding (performance bias and detection
bias)
Measurement of vision
High risk Participant and outcome assessors were
not masked, unclear if care providers were
masked
Incomplete outcome data (attrition bias)
All outcomes
Low risk See Results, Appendix 8, Figure 3 . UNI-
LATERAL: 81%followed at 2 years in both
study arms; loss to follow-up was balanced
but causes of loss were not reported
Selective reporting (reporting bias) Low risk Development of CNV and atrophy, as well
as loss of ≥ 3 lines of VA were well defined
and relevant outcomes
Other bias High risk Enrolment in these pilot studies was sus-
pended under recommendation by the
Data and Safety Monitoring Committee
(DSMC) because there was a higher inci-
dence of CNV within 12 months of study
enrolment in laser-treated eyes than in ob-
served eyes, predominantly in the Fellow
Eye Study
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DLS
Methods Method of allocation: randomisation was conducted with a computerised weighted coin
method in the Research and Development office. The randomisation assignment was
provided by telephone, and the clinic co-ordinator printed the randomisation assign-
ment on the participant’s baseline form. The clinical investigator was then informed
of the randomisation allocation. All study eyes of eligible participants in the UNILAT-
ERAL group were randomised. The study eye was randomised to laser treatment or no
laser treatment. All right eyes of eligible participants in the BILATERAL group were
randomised to laser treatment or no laser treatment; the fellow eye received the alternate
treatment
Masking: participant: unclear; provider: unclear; outcome assessor: masked VA examiner
Exclusions after randomisation: none reported
Losses to follow-up: UNILATERAL: at 3 years, VA was obtained in 73/92 (80.7%)
laser-treated eyes vs. 66/85 (77.6%) control eyes. Development of CNV was recorded
in 91/92 treated eyes and 85/85 control eyes. BILATERAL: VA obtained in 72/105
participants at 3 years, and CNV development assessed in 103/105 eyes at 3 years
Unusual study design: some participants had both eyes randomised (BILATERALgroup)
and within-person correlation was taken into account
Participants Country: UK
BILATERAL: number randomised: 105 participants (210 eyes). Age: 70.1 years (range:
52 to 100). Sex: 31 men/74 women
UNILATERAL: number randomised: 177 participants. Age: 72 years (range: 54 to 87)
. Sex: 80 men/97 women
Inclusion criteria: drusen with/without focal RPE hyperpigmentation in the study eye
and CNV in the fellow eye; BCVA at least 6/12 (20/40); aged at least 50 years
Exclusion criteria: geographic atrophy in either eye; any other eye disease able to influence
VA; allergy to fluorescein
Interventions Treatment: argon green/yellow dye laser with 200-µm spot size, 0.2 second duration and
the lowest energy to produce a very faint burn; overall 12 burns: 4 burns placed 750 µm
from FAZ centre (12, 3, 6, 9 o’clock), and 8 burns 1500 µm from FAZ centre (12, 1.
30, 3, 4.30, 6, 7.30, 9. 10.30, 12 o’clock); drusen treated directly if they were coincident
with protocol treatment allocation
Control: observation
Outcomes Proportion of participants who developed CNV; VA
Notes Protocol of treatment revised after 23 months: 12 burns (0.2 seconds to 200-µm spot
size) placed in circular pattern at 1000 µm from FAZ centre
Supported in part by Deutsche Forschungsgemeinschaft (DFG GR 1007/3-1 and Ho
1926/1-2) and the Deutsche Akademischer Austauschdienst ARC IX-95/32 (MG)
COI declaration: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated method
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DLS (Continued)
Allocation concealment (selection bias) Low risk The clinical investigator was informed of
the randomisation allocation by the co-or-
dinator by telephone after eligibility was as-
sessed
Blinding (performance bias and detection
bias)
Development of CNV/geographic atrophy
Low risk Unmasked study, but CNV occurrence was
sufficiently objective as a diagnosis to be
considered unbiased
Blinding (performance bias and detection
bias)
Measurement of vision
Low risk Masked VA examiners. Participants cannot
be masked since no sham procedure was
mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk See Results, Appendix 8. Losses to follow-
up were balanced but causes were not re-
ported; no risk of bias given the paired
study design for the BILATERAL study
arm
Selective reporting (reporting bias) Low risk Development of CNV and atrophy, as well
as loss of ≥ 3 lines of VA were well defined
and relevant outcomes
Other bias High risk The trial was stopped early after an interim
analysis suggested that laser treatment in-
duced CNV in treated eyes of participants
in the unilateral group
Figueroa 1994
Methods Method of allocation: not reported. 1 eye of participants with bilateral drusen was
assigned to treatment and the fellow eye to control
Masking: not reported if participants and providers, but participants could not bemasked
since there was no sham procedure. VA examiners were masked
Exclusions after randomisation: none reported
Losses to follow-up: since they reported on results at last examination (mean follow-up
3 years), assessing the impact of loss to follow-up was difficult
Unusual study design: paired or bilateral study; authors also reported on a parallel case
series of people with CNV in 1 eye who were all treated in the fellow eye
Participants Country: Spain
Number randomised: 30 participants (60 eyes)
Age: 69 years (range: 62 to 74)
Inclusion criteria: AMD with large confluent soft drusen involving the fovea
Exclusion criteria: not specified
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Figueroa 1994 (Continued)
Interventions Treatment: green argon laser; 0.1 mW, 0.1 seconds, 100-µm spot; laser spot on drusen
in the temporal fovea, or grid pattern if drusen > 300 µm
Control: observation
Duration: mean 3 years (range: 1.5 to 5)
Outcomes Occurrence of CNV, reduction of drusen, VA
Notes Drusen resolution possible also for drusen located far from the laser application
Supported in part by National Institutes of Health grant NEI EY12769 and 5 P30 EY
01583, the Vivian Simkins Lasko Research Fund, the Nina C. Mackall Trust, and an
unrestricted grant from Research to Prevent Blindness, New York, NY
COI declaration: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
Development of CNV/geographic atrophy
Low risk Unmasked study, but CNV occurrence was
sufficiently objective as a diagnosis to be
considered unbiased
Blinding (performance bias and detection
bias)
Measurement of vision
Low risk Masked visual examiner
Incomplete outcome data (attrition bias)
All outcomes
Low risk See Results, Appendix 8. Data at mean fol-
low-up were reported. Since 12/30 partic-
ipants were followed for < 3 years, it was
difficult to assess the impact of this type
of reporting. However, in the updated ver-
sion of this review, we considered missing
data as no risk of bias in bilateral studies
because a participant with paired treatment
and control eyes is missed
Selective reporting (reporting bias) Unclear risk Development of CNV and atrophy, as well
as loss of ≥ 3 lines of VA were well defined
and relevant outcomes
Other bias Unclear risk Unclear
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Frennesson 1995
Methods Method of allocation: not reported; in 5 participants with both eyes eligible the eye with
better VA was randomised
Masking: participant: unclear; provider: unclear; outcome: unclear
Exclusions after randomisation: none reported
Losses to follow-up: 2/19 participants in the treated group vs. 0/19 in the control group
lost to follow-up at 3 years
Unusual study design
Participants Country: Sweden
Number randomised: 38 participants
Age: 71.6 years (SD 6.5) treated participants; 68.5 years (SD 6.2) control participants
Inclusion criteria: soft drusen; VA at least 0.8
Exclusion criteria: CNV, PED, pigmentary clumping, macular atrophy, haemorrhage,
any other eye disorder that could affect VA
Interventions Treatment: argon green laser with 200-µm spot size, 0.05 seconds’ duration, power
to produce a barely visible lesion. Treatment with a temporal horse shoe-shaped area
extending to the vascular arcades, with direct treatment of the drusen
Control: observation
Duration: 3-8 years
Outcomes Anatomic: mean drusen area, development of CNV. Functional: Snellen VA; colour
vision (Farnsworth panel D-15); central visual field (Humphrey 10-2)
Notes The study was supported by grants from the Swedish Medical Research Council (Project
No 12X-734), from the Research Committee of the County of Östergötland and from
Synfrämjandet’s Research Foundation
COI declaration: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
Development of CNV/geographic atrophy
Low risk Unmasked study, but CNV occurrence was
sufficiently objective as a diagnosis to be
considered unbiased
Blinding (performance bias and detection
bias)
Measurement of vision
Unclear risk Not reported. Participants could not be
masked since no sham procedure was men-
tioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk See Results, Appendix 8. 2/19 (11%) par-
ticipants in the treated group vs. 0/19 in the
control group lost to follow-up at 3 years;
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Frennesson 1995 (Continued)
causes of loss to follow-up not reported
Selective reporting (reporting bias) Low risk Development of CNV and atrophy, as well
as loss of ≥ 3 lines of VA were well defined
and relevant outcomes
Other bias Unclear risk Unclear
Frennesson 2009
Methods Method of allocation: randomisation generated as a permuted block design; the ran-
domisation was delivered from Linkoping University Hospital. Enrolling doctors were
not masked to treatment allocation (personal communication)
Masking: participant: yes; provider: no; outcome: no (personal communication)
Outcome: incidence of CNV, VA
Follow up: mean 3.7 years (range 1-7.5 years)
Exclusions after randomisation: none reported
Losses to follow-up: two-thirds of participants were followed up to 4 years, with losses
balanced across groups
Unusual study design: nothing reported
Participants Country: Sweden, Denmark, Finland
Number randomised: 135 participants
Age: mean 70.4 years
Inclusion criteria: people with soft drusen with or without mild pigmentary changes;
VA ≥ 0.8 (20/25) in the study eye, aged ≥ 50 years
Exclusion criteria: including pigmentary clumping, PED,CNV, haemorrhage ormacular
atrophy, and any other ophthalmological disease in the study eye that might possibly
influence the outcome
Interventions Treatment: laser treatment (subthreshold or barely visible laser spots). About 100 mild
argon green laser spots with a size of 200 µm and a duration of 0.05 seconds
Unspecified control, possibly observation only
Outcomes VA, occurrence of CNV
Notes The study was supported by grants from the Health Research Council in the South-East
Region of Sweden, CrownPrincessMargareta’s Foundation for the VisuallyHandicapped
and Synframjandet’s Research Foundation
COI information: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, permuted block de-
sign
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Frennesson 2009 (Continued)
Allocation concealment (selection bias) High risk Randomisation was
delivered from Linkoping University Hos-
pital. Enrolling doctors were not masked to
treatment allocation
Blinding (performance bias and detection
bias)
Development of CNV/geographic atrophy
Low risk Participants masked and doctors un-
masked, but CNV occurrence was suffi-
ciently objective as a diagnosis to be con-
sidered unbiased
Blinding (performance bias and detection
bias)
Measurement of vision
High risk Care providers were unmasked. Partici-
pants could not be masked since no sham
procedure was mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk Mean follow-up time was about 3.5 years
and two-thirds of participants were fol-
lowed up to 4 years, with losses bal-
anced across groups. Study authors re-
ported causes of missingness were death or
illness in 5 of 6 cases at 2 years
Selective reporting (reporting bias) Low risk Main relevant outcome measure were re-
ported
Other bias Unclear risk Unclear
Laser to Drusen Study 1995
Methods Method of allocation: computer-generated randomisation list with randomly selected
block sizes. Allocation groups: observation vs. laser (1 : 1), laser further divided (1 : 1)
in temporal vs. nasal and temporal treatment
Masking: participant: unclear; provider: unclear; outcome: unclear
Exclusions after randomisation: none reported
Losses to follow-up: 7/47 (15%) of treatment group and 10/52 (19%) of control group
seen at 2 years
Participants Country: US
Number randomised: 99 participants
Age: mean 74 years (SD 6.6), range 55 to 84 years
Sex: 69.7% women
Inclusion criteria:
• large drusen (> 63 µm in diameter) and focal hyperpigmentation, and no
neovascular AMD in 1 eye only (study eye)
• evidence of neovascular AMD (CNV, disciform scar, laser scar for CNV) in 1 eye
only (fellow eye)
• VA 20/40 or better in study eye (other information says 20/50 or better)
• no significant co-existing ocular disorder in study eye
• aged ≥ 50 years
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Laser to Drusen Study 1995 (Continued)
Exclusion criteria:
• history of laser surgery or vitreous surgery in study eye
• low probability of completing 2-year follow-up schedule (poor health, live far
from clinical centre, unwilling to return)
• geographic atrophy within 3000 µm of foveal centre
• other conditions associated with CNV, including pathological myopia (spherical
equivalent exceeding -8.00 dioptres or clinical evidence of lacquer cracks), angioid
streaks, histo spots, pattern dystrophies of RPE, etc. in study eye
• severe non-proliferative or worse diabetic retinopathy or diabetic macular oedema
in study eye
• other progressive ocular disease that could impair VA such as glaucoma in the
study eye
• lensectomy or intraocular lens implantation within 3 months
Interventions Laser wavelength: dye yellow laser (577 nm) or infrared diode (very early - was dis-
continued). Number of burns: various, 2 scatter patterns described below; spot size: 50
µm; duration: 0.1 seconds; intensity: very light grey burn (just visible); no treatment
within 500 µm of foveal centre and beyond 3000 µm from foveal centre; scatter burns
approximately 2-3 burn widths apart, trying to avoid placing burns directly over focal
clumps of hyperpigmentation. Do not have to place directly on drusen, but in placing
scatter, small placement changes (< 50 µm) should be done to centre spot on drusen
Pattern 1: (temporal = 180 degree) - not placed in nasal portion of macula (vertical line
intersects foveal centre)
Pattern 2: (temporal and nasal = 360 degree) - burns placed in scatter both nasal and
temporal portion of macula (exclusive of central macula within 500 µm of foveal centre
and not beyond 3000 µm of foveal centre)
Outcomes Development of CNV; VA; information on other outcomes not available
Notes Randomisation changed - originally 1 : 1 (laser vs. observation), then laser group ran-
domised 1 : 1 (infrared diode vs. yellow dye) - each colour laser was randomised 1:1
(temporal vs. temporal and nasal)
The red diode laser arm was stopped early (probably December 1995)
Pilot study nature - so some clinical centres did not do all tests (reading, contrast) - not
all clinical photographs graded
Funding source unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated. Randomly selected
block size (Marta MGilson, personal com-
munication)
Allocation concealment (selection bias) Low risk Serially numbered sealed opaque en-
velopes. Co-ordinator had to fill out check-
list - document eligibility - then open se-
quentially numbered envelope, record date
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Laser to Drusen Study 1995 (Continued)
opened, time opened, participant number,
name code and sign the form (2 copies
- keep 1, and fax other to co-ordinating
centre within 24 hours of opening). Faxed
forms were later mailed to co-ordinating
centre (Marta M Gilson personal commu-
nication)
Blinding (performance bias and detection
bias)
Development of CNV/geographic atrophy
Low risk Participants: unclear; care providers: oph-
thalmologists (applying laser) were not
masked; care providers - co-ordinators: un-
clear; outcome assessors: PhotographRead-
ing Centre graders were to be masked, but
it was possible that some of the laser scars
may have unmasked the graders (Marta M
Gilson, personal communication)
Blinding (performance bias and detection
bias)
Measurement of vision
Unclear risk VA examiners: unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk See Results, Appendix 8, Figure 3. 7/
47 (15%) of treatment group and 10/52
(19%) of control group lost at 2 years. No
information on reasons for loss to follow-
up
Selective reporting (reporting bias) Low risk Outcomes selected by review author
Other bias Unclear risk Unclear
Little 1995
Methods Methodof allocation: after participants eligibilitywas ascertained andparticipant consent
was obtained, 1 eye was randomised to photocoagulation treatment; the right eye was
assigned to treatment if participant’s birth date was an odd month, the left if it was an
even month
Masking: participant: unclear; provider: unclear; outcome assessor: unclear
Exclusions after randomisation: none reported
Losses to follow-up: a minimum 1-year follow-up was obtained (mean 3.2 years)
Unusual study design: paired study
Participants Country: US
Number randomised: 27 participants (54 eyes)
Age: mean 69.7 years
Sex: 9 men/18 women
Inclusion criteria: symmetrical drusen; minimum drusen size 100 µm; at least 20 drusen
or 10 drusen + 2 drusen at least 500 µm in diameter; drusen within 500 µm from
foveola; VA at least 20/60
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Little 1995 (Continued)
Exclusion criteria: PED; atrophy; subretinal fluid, haemorrhage, exudate; any other eye
disorder which could affect VA
Interventions Treatment: 577- to 620-nm wavelength laser with 100-200 µm spot size, 0.05-0.1
seconds’ duration, 100-200 power. Direct treatment of the drusen
Control: observation
Duration: 1- to 6-year follow-up
Outcomes Snellen VA; colour vision (Farnsworth panel D-15 colour-test); central visual field with
Humphrey 10-2
Notes No COI for any author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk After participants eligibility was ascer-
tained and participant consent was ob-
tained, 1 eye was randomised to photoco-
agulation treatment; the right eye was as-
signed to treatment if person’s birth date
was an odd month, the left if it was an even
month
Allocation concealment (selection bias) High risk See above, the enrolling researcher could
have foreseen which eye would have been
treated. Nonetheless, this can be irrelevant
since both eyes of each participant were in-
cluded, i.e. there was no risk of confound-
ing
Blinding (performance bias and detection
bias)
Development of CNV/geographic atrophy
Low risk Unmasked study, but CNV occurrence was
sufficiently objective as a diagnosis to be
considered unbiased
Blinding (performance bias and detection
bias)
Measurement of vision
High risk Not reported. Participants could not be
masked since no sham procedure was men-
tioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk Unclear: only last visit data reported, thus
being impossible to reconstruct the pattern
of missing data; 4/27 participants were fol-
lowed for ≥ 1 year but < 2 years. However,
in the updated version of this review, we
considered missing data as no risk of bias in
bilateral studies because a participant with
paired treatment and control eyes is missed
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Little 1995 (Continued)
Selective reporting (reporting bias) Low risk Development of CNV and atrophy, as well
as loss of ≥ 3 lines of VA were well defined
and relevant outcomes
Other bias Unclear risk Unclear
Olk 1999
Methods Method of allocation: not reported; BILATERAL: 1 eye was assigned to treatment and 1
eye to observation.UNILATERAL: 1 eye eligible that eyewas assigned to either treatment
or observation. BILATERAL/UNILATERAL: eyes assigned to treatment were further
randomised to either ’visible’ or ’subthreshold’ treatment
Masking: participant: unclear; provider: unclear; outcome: unclear
Exclusions after randomisation: 25/152 participants (35 eyes) were enrolled initially in
the pilot study but subsequently determined to be ineligible for various reasons, mainly
violation of inclusion criteria
Losses to follow-up: at 24 months, 33 eyes had missed visits: 9 eyes (4 observation, 2
visible, 3 subthreshold) were in deceased participants, 14 eyes were in the observation
group, and 10 eyes were in the treatment group (5 eyes, visible; 5 eyes, subthreshold)
Unusual study design: some eyes
Participants Country: US
Number randomised: BILATERAL: 77 participants (154 eyes) with both eyes eligible.
UNILATERAL: 75 participants (75 eyes) with 1 eye eligible (unilateral study arm), that
eye was assigned to either treatment or observation
Enrolment period: July 1994 to June 1996
Sex: 152 participants enrolled; 57 men, 95 women
Age: mean 74.5 years, range 54-88 years
Inclusion criteria: aged > 50 years; diagnosis of AMD with ≥ 5 large (≥ 63 µm), soft
drusen within 2250 µm of the centre of the FAZ in both eyes (bilateral study arm) or in
1 eye (unilateral study arm) if the fellow eye had evidence of exudative AMD; and VA
of ≥ 20/63 on the ETDRS chart in all eligible eyes
Exclusion criteria: exudative macular degeneration in either eye for bilateral participants
and in both eyes for unilateral participants; other ocular diseases
Interventions Eyes were treated with a slit-lamp integrated diode photocoagulator using 810-nm wave-
length (IRIS Medical OcuLight SLx; IRIDEX Corp., Mt. View, CA). 48 diode laser
lesions of 125 mmwere applied in 4 concentric circles outside the FAZ in a scatter or grid
pattern between 750 and 2250 mm from the centre of the fovea. Test spot laser lesions
were applied to the retina nasal to the optic nerve using 200-millisecond duration, and
the power was increased to produce a mild grey lesion (visible burn). For eyes assigned
to visible treatment, this intensity was then applied in a grid pattern as described above.
For eyes assigned to subthreshold treatment, the energy needed for the visible test burn
was kept constant, but the duration was halved to 100 milliseconds and treatment then
carried out. Only 1 laser treatment was applied to each eye throughout the duration of
the study
Outcomes Anatomic: reduction of drusen, development of CNV. Functional: VA
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Olk 1999 (Continued)
Notes Within-person correlation of outcomes in the bilateral arm not analysed and reported
Supported in part by grants from IRIS Medical, Mountain View, CA (producer of the
laser used in the study), and The University of Pittsburgh Eye and Ear Foundation,
Pittsburgh, PA
COI declaration: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
Development of CNV/geographic atrophy
Low risk Unmasked study, but CNV occurrence was
sufficiently objective as a diagnosis to be
considered unbiased
Blinding (performance bias and detection
bias)
Measurement of vision
High risk Not reported. Participants could not be
masked since no sham procedure was men-
tioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk See Results, Appendix 8 and Figure 3.
Losses to follow-up: at 24 months, 33 eyes
had missed visits: 9 eyes (4 observation, 2
visible, 3 subthreshold) were in deceased
participants, 14 eyes were in the obser-
vation group, and 10 eyes were in the
treatment group (5 eyes, visible; 5 eyes,
subthreshold). Causes of loss to follow-up
other than death were not reported. In the
updated version of this review, we consid-
ered missing data as no risk of bias in bi-
lateral studies because a participant with
paired treatment and control eyes ismissed.
Thus, only losses in unilateral armwas con-
sidered
Selective reporting (reporting bias) Low risk Development of CNV and atrophy, as well
as loss of ≥ 3 lines of VA were well defined
and relevant outcomes
Other bias Unclear risk Unclear
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PTAMD bilateral 2009
Methods Method of allocation: study eyes were assigned randomly to either treatment or obser-
vation by a computer-generated, centre-specific, variable block size randomisation at a
1 : 1 ratio. These random assignments were concealed in opaque envelopes that were
opened only upon enrolment of an eligible person who gave consent
Masking: participant: unclear; provider: unclear; outcome: unclear
Participant: 1278 eyes of 639 participants
Outcome: development of CNV and change in best-corrected VA
Exclusions after randomisation: none reported
Losses to follow-up: 374/639 (54.3%) participants followed to 2 years
Unusual study design: paired study
Participants Country: US
Number randomised: 1278 eyes of 639 participants
Enrolment period: April 1996 to March 2000
Mean age: 73.0 years (SD 2.5)
Inclusion criteria: aged ≥ 50 years. Eligible eye must have had BCVA of ≥ 20/63 on
the ETDRS chart in both eyes; AMD with ≥ 5 drusen that were ≥ 63 µm in diameter
and were located within 2250 µm of the centre of the fovea; unilateral participants must
have had 1 eye ineligible due to vision loss that was attributed to advanced AMD
Exclusion criteria: other ocular disease causing visual loss
Interventions Eyes randomised to treatment received a single-session treatment of a grid of 48 diode
laser lesions of 125 µm in diameter. Laser treatment was applied in an annular grid that
extended from 0.5 (750 µm) to 2.0 (3000 µm) disc diameters from the centre of the
FAZ. A slit lamp-based diode laser photocoagulation system (IRIS Medical, Mountain
View, CA) emitting energy at 810 nm was used to deliver the laser treatment. Laser
lesions were placed in a subthreshold manner by first delivering test spot(s) of 200-
millisecond duration placed outside of the macula at a low power (e.g. 200 mW) and
then incrementally increasing the power in small (50 mW) increments until a faint grey
(threshold) lesion could be detected visually through the treatment lens.While the power
setting was left unchanged, the pulse duration was reduced to a 100-millisecond interval
to achieve an invisible subthreshold lesion. Laser lesions were then scattered within the
annular grid as defined above, beginning by placing 12 spots in a given quadrant and
then proceeding to adjacent quadrants to complete the treatment pattern. The drusen
were not targeted specifically or preferentially. If a visible lesion was produced while
the annular grid treatment was performed, the power setting was reduced to achieve
subthreshold lesions with the remainder
Outcomes Anatomic: drusen reduction, development of CNV. Functional: VA
Notes Supported by IRIDEX Corporation, Mountain View, CA (the producer of the laser used
in the study); the Eye and Ear Foundation of Pittsburgh, Pittsburgh, PA; Research to
Prevent Blindness, Inc., New York, NY and unrestricted funds from several participating
centres
COI declaration: the authors had no financial or proprietary interest in the materials
presented
Risk of bias
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PTAMD bilateral 2009 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, centre-specic, vari-
able block size randomisation at a 1 : 1 ratio
Allocation concealment (selection bias) Low risk These random assignments were concealed
in opaque envelopes that were opened only
upon enrolment of an eligible person who
gave consent
Blinding (performance bias and detection
bias)
Development of CNV/geographic atrophy
Low risk Unmasked study, but CNV occurrence was
sufficiently objective as a diagnosis to be
considered unbiased
Blinding (performance bias and detection
bias)
Measurement of vision
Unclear risk Not reported,
masking of care providers and photograph
graders might be achieved since subthresh-
old photocoagulation should not generate
visible scars. Participants cannot bemasked
since no sham procedure was mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk Large proportion of participants lost to fol-
low-up, but this was unlikely to bias effect
estimates since this was a paired study. In
the updated version of this review, we con-
sidered missing data as no risk of bias in
bilateral studies because a participant with
paired treatment and control eyes is missed
Selective reporting (reporting bias) Low risk Development of CNV and atrophy, as well
as loss of ≥ 3 lines of VA were well defined
and relevant outcomes
Other bias Unclear risk Unclear
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PTAMD unilateral 2002
Methods Method of allocation: study eyes were assigned randomly to either treatment or obser-
vation by a computer-generated, centre-specific, variable block size randomisation at a
1 : 1 ratio. These random assignments were concealed in opaque envelopes that were
opened only upon enrolment of an eligible person who gave consent
Masking: participant: unclear; provider: unclear; outcome: unclear
Exclusions after randomisation: not reported
Losses to follow-up: at 1 year, 184/244 (75%) participants followed (5 deaths), 92 treated
eyes and 99 control eyes followed. At 3 years, 124/244 (51%) participants followed (20
deaths), 64 treated eyes and 55 control eyes followed
Unusual study design: another arm of the study included participants with both eyes
eligible, but this report deals with unilateral participants only
Participants Country: US
Number randomised: 244 participants
Age: mean 75.4 years for treated participants, 75.1 years for observed participants
Gender (% women): 59.3 treated participants, 61.5 observed participants
Inclusion criteria: aged≥ 50 years. Eligible eye must have had BCVA of≥ 20/63 on the
ETDRS chart; AMD with ≥ 5 drusen that were 63 µm in diameter and were located
within 2250 µm of the centre of the fovea; unilateral participants must have had 1 eye
ineligible due to vision loss that was attributed to advanced AMD
Exclusion criteria: other ocular disease causing visual loss
Interventions Eyes randomised to treatment received a single-session treatment of a grid of 48 diode
laser lesions of 125 µm in diameter. Laser treatment was applied in an annular grid that
extended from 0.5 (750 µm) to 2.0 (3000 µm) disc diameters from the centre of the
FAZ. A slit lamp-based diode laser photocoagulation system (IRIS Medical, Mountain
View, CA) emitting energy at 810 nm was used to deliver the laser treatment. Laser
lesions were placed in a subthreshold manner by first delivering test spot(s) of 200-
millisecond duration placed outside of the macula at a low power (e.g. 200 mW) and
then incrementally increasing the power in small (50 mW) increments until a faint grey
(threshold) lesion could be detected visually through the treatment lens.While the power
setting was left unchanged, the pulse duration was reduced to a 100-millisecond interval
to achieve an invisible subthreshold lesion. Laser lesions were then scattered within the
annular grid as defined above, beginning by placing 12 spots in a given quadrant and
then proceeding to adjacent quadrants to complete the treatment pattern. The drusen
were not targeted specifically or preferentially. If a visible lesion was produced while
the annular grid treatment was performed, the power setting was reduced to achieve
subthreshold lesions with the remainder
Outcomes Anatomic: drusen reduction, development of CNV. Functional: VA
Notes Supported by IRIDEX Corporation, Mountain View, CA (the producer of the laser used
in the study); the Eye and Ear Foundation of Pittsburgh, Pittsburgh, PA; Research to
Prevent Blindness, Inc., New York, NY and unrestricted funds from several participating
centres
COI declaration: the authors had no financial or proprietary interest in the materials
presented
Risk of bias
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PTAMD unilateral 2002 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, centre-specific, vari-
able block size randomisation
Allocation concealment (selection bias) Low risk Random assignments were concealed in
opaque envelopes that were opened only
upon enrolment of an eligible person who
gave consent
Blinding (performance bias and detection
bias)
Development of CNV/geographic atrophy
Low risk Unmasked study, but CNV occurrence was
sufficiently objective as a diagnosis to be
considered unbiased
Blinding (performance bias and detection
bias)
Measurement of vision
Unclear risk Not reported, masking of care providers
and photograph graders might be achieved
since subthreshold photoco-
agulation should not generate visible scars.
Participants could not be masked since no
sham procedure was mentioned
Incomplete outcome data (attrition bias)
All outcomes
High risk See Results, Appendix 8, Figure 3. Survival
analysis used. Losses to follow-up: at 1 year,
184/244 (75%) participants followed (5
deaths), 92 treated eyes and 99 control eyes
followed. At 3 years, 124/244 (51%) par-
ticipants followed (20 deaths), 64 treated
eyes and 55 control eyes followed. Causes
of loss other than death were not reported
Selective reporting (reporting bias) Low risk Development of CNV and atrophy, as well
as loss of≥ 3 or more lines of VA were well
defined and relevant outcomes
Other bias Unclear risk Unclear
AMD: age-related macular degeneration; AREDS: Age-Related EyeDisease Study; BCVA: best-corrected visual acuity; CNV: choroidal
neovascularisation;COI: conflict of interest; ETDRS: EarlyTreatmentDiabetic Retinopathy Study; FAZ: foveal avascular zone;MPS:
Macular Photocoagulation Study; PED: pigment epithelial detachment; RPE: retinal pigment epithelial; SD: standard deviation;
VA: visual acuity; vs.: versus.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Guymer 2014 Non-randomised study assessing a novel, ultra-low energy nanosecond laser (retinal rejuvenation therapy) to slow
progression of early age-related macular degeneration. Drusen reduction was achieved in 44% of treated eyes and
22% of untreated fellow eyes
Huang 2011 Paired controlled study (10 participants): 1 eye randomly assigned to laser, the fellow eye to control. However,
authors reported that participants could have chosenwhich eye had to receive laser, so unclearwhether randomisation
was maintained
Sarks 1999 Comparative study but no randomisation
Sigelman 1991 Case report
Characteristics of studies awaiting assessment [ordered by study ID]
Sivagnanavel 2004
Methods Prospective, double masked, randomised controlled trial at King’s College Hospital, London, UK
Participants People with subfoveal choroidal neovascularisation from age-related macular degeneration in 1 eye and significant
drusen (> 5 large drusen or > 20 small drusen) in the fellow eye
Interventions Drusen photocoagulation by means of diode laser using large spot size, low energy and long duration (4200 µm x
400 mW x 60 seconds); control group received sham treatment (laser with no energy)
Outcomes Fundus changesmeasured with photography, visual acuity, contrast sensitivity and colour contrast sensitivity recorded
every 3 months
Notes -
Characteristics of ongoing studies [ordered by study ID]
Beaumont 2011
Trial name or title Prophylactic Laser Photocoagulation of Drusen in Early Age-Related Macular Degeneration
Methods Paired controlled study, contact author reported random assignment
Participants Quote: “121 consecutive patients with large, ill defined drusen within the perifoveal zone of both maculae
were studied prospectively”
Interventions Quote: “One eye was treated with sub-threshold intensity photocoagulation to the drusen, sparing the fovea.
The fellow eye served as the control”
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Beaumont 2011 (Continued)
Outcomes Quote: “The mean follow-up duration was 65.0 ± 24.4 months. The treated eyes lost a mean of 0.2 ± 2.5
logMAR lines, compared to 0.9 ± 2.7 lines in the control group (p = 0.051). CNV [choroidal neovasculari-
sation] developed in 5 (4.1%) of the treated eyes and 10 (8.3%) of the control eyes, while GA [geographic
atrophy] developed in 12 (9.9%) of the treated and 8 (6.6%) of the control eyes (p = 0.291).”
Starting date Unknown
Contact information H. Kwon Kang, Retina & Vitreous Centre, Sydney, NSW, Australia
Notes Reported as ongoing and unpublished by contact author
NCT01790802
Trial name or title Laser Intervention in Early Age-Related Macular Degeneration Study (LEAD)
Methods Randomised controlled trial
Participants Inclusion criteria:
• Men or women aged 50-95 years at the time of consent
• BCVA of 6/12 (20/40) or better in each eye
• Bilateral high-risk early AMD: at least 1 druse ≥ 125 µm within an inner macular zone (a circle with a
radius of 1500 µm centred on the fovea) with or without pigment
• A MAIA static threshold sensitivity < 25 dB at any point, within a customised grid, as measured using
a MAIA device), at the same location of the 1 eye on 2 separate occasions
• Pupil dilation of ≥ 5 mm in each eye
• Fundus photographs, OCT and FAF images of adequate quality as assessed by the LEAD Image
Reading Centre
• Ability and willingness to consent, and be randomised, to the 2RT active or sham laser treatment, and
all qualification and follow-up phases of the study
Exclusion criteria:
• Any evidence of definite geographic atrophy within the macula (a circle with a radius of 3000 µm
centred on the fovea). Geographic atrophy is defined as an area of partial or complete depigmentation of the
RPE in the fundus photographs that has at least 2 of the following 3 characteristics: roughly round or oval
shape, sharp margins and visibility of underlying large choroidal vessels.
• Any black (hypofluorescent) area of FAF consistent with GA (roughly round or oval shape, sharp
margins), and corroborated on colour photography as a patch of hypopigmentation
• Any evidence of ’preclinical atrophy’ as determined on OCT: loss of the outer retina (RPE and
photoreceptors on the cube scan (Spectralis OCT) (49 horizontal B scans, 120 µm apart over a 20 x 20
degree scan). This covers approximately 6 x 6 mm in an emmetropic eye (note: peri-papillary atrophy
further than 1500 µm from the fovea is allowed)
• Current CNV, or past evidence of CNV in either eye.
• Any other experimental treatment for AMD, excluding dietary supplements, received in the past 12
months or thought likely to chronically change the course of the participant’s retinal disease
• Any OCT showing evidence of intraretinal fluid, or subretinal fluid for which CNV cannot be
excluded as a cause
• A subfoveal pigment epithelial detachment/drusenoid detachment > 1000 µm in diameter
• Other macular disease with subretinal deposits not typical of AMD, e.g. Malattia Leventinese, Sorsby
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NCT01790802 (Continued)
fundus dystrophy and Alport’s syndrome
• Ocular disease in either eye, other than AMD, which significantly compromises the ability to treat or
visualise the fundus or would compromise the ability to assess any effect following laser application
including; diabetic retinopathy (unless limited to < 10 microaneurysms or small retinal haemorrhages, or
both, without retinal thickening on OCT), angioid streaks, central serous choroidopathy, optic atrophy,
epiretinal membrane involving the macula, pigmentary abnormalities of the retina atypical of AMD (e.g.
myopia, pattern dystrophy or chronic central serous retinopathy), myopic crescent wider than 50% of the
longest diameter of the optic disc, or closer than 1500 µm to the fovea, macular hole or pseudohole, retinal
vein occlusion, active uveitis, presumed ocular histoplasmosis syndrome, choroidal naevus within 2 DD of
the fovea associated with depigmentation or overlying drusen, if these drusen are used to determine
eligibility. Amblyopia in either eye even if BCVA is better than 6/12 (20/40)
• Known allergic hypersensitivity to fluorescein
• Previous retinal or other ocular surgical procedures, the effects of which may now or in the future
complicate assessment of the progression of AMD
• Requirement for any systemic or ocular medication known to be toxic to the retina, such as:
deferoxamine, chloroquine/hydroxychloroquine (Plaquinil), chlorpromazine, phenothiazines and
ethambutol
• Any serious systemic disease that will preclude a 3-year survival and regular attendance for follow-up
• Sensitivity to contact lens application
• Any condition that would make adherence to the examination schedule for 3 years difficult or unlikely
• Any history of prior laser surgery to the retina
• Intraocular pressures of 26 mm Hg or higher or if there is some reason to believe the participant may
have glaucoma (e.g. demonstrated field defect typical of glaucoma, history of medical, surgical or laser
intervention for the treatment of glaucoma, or disc/nerve fibre layer defects suggestive of glaucoma)
• Significant cataract: nuclear cataract grade 2 or 3, cortical cataract Grade 2 or 3 or posterior
subcapsular cataract Grade 2 or 3, by Simplified Cataract Grading System (WHO Cataract Grading Group)
Interventions Experimental: active laserTwelve 2RT nanosecond laser shots in 2 arcs of 6 shots superiorly and 6 shots
inferiorly, inside the retinal vascular arcades at an approximate distance from the fovea of 3000 µm, with
approximately 1 laser spot diameter between them
Sham comparator: sham laser procedure. To simulate laser application the maximum illumination button
will be briefly pressed by the operating physician at each of the 12 locations described above where and when
the laser would normally be applied. The laser remains in standby mode preventing accidental laser firing
Outcomes Primary outcomes:
• progression to advanced AMD in the treated eye (time frame: 36 months)
• rate of progression to advanced AMD, either CNV, geographic atrophy or preclinical atrophy, in the
study eye of treatment group compared to the sham procedure group
Secondary outcomes:
• progression to advanced AMD in the untreated eye (time frame: 36 months), rate of progression to
advanced AMD, CNV, GA or preclinical atrophy in the fellow (untreated) eye
Other outcomes: reversal of early clinical indicators of AMD (time frame: 36months), reversal of early clinical
indicators of AMD (drusen area)
Improvements in visual acuity (time frame: 36 months)
Starting date Estimated enrolment: 250
Study start date: November 2011
Estimated study completion date: June 2017
Estimated primary completion date: June 2017 (final data collection date for primary outcomes)
49Laser treatment of drusen to prevent progression to advanced age-related macular degeneration (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT01790802 (Continued)
Contact information Centre for Eye Research Australia - Royal Victorian Eye & Ear Hospital East Melbourne, Victoria, Australia,
3002
Emily EA Caruso, B Orth & OphSc +61 3 9929 emily.caruso@unimelb.edu.au
Notes
AMD: age-related macular degeneration; BCVA: best-corrected visual acuity; CNV: choroidal neovascularisation; GA: geographical
atrophy; FAF: fundus autofluorescence; MAIA: macular integrity assessment; OCT: optical coherence tomography; RPE: retinal
pigment epithelial.
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D A T A A N D A N A L Y S E S
Comparison 1. Photocoagulation versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Development of choroidal
neovascularisation (CNV)
11 3580 Odds Ratio (M-H, Random, 95% CI) 1.07 [0.79, 1.46]
1.1 Bilateral studies 6 2873 Odds Ratio (M-H, Random, 95% CI) 0.99 [0.72, 1.36]
1.2 Unilateral studies 7 707 Odds Ratio (M-H, Random, 95% CI) 1.04 [0.60, 1.79]
2 Development of CNV:
sensitivity analysis assuming
moderate correlation (0.5) for
bilateral studies
11 Odds Ratio (Random, 95% CI) 1.11 [0.82, 1.51]
2.1 Bilateral studies 6 Odds Ratio (Random, 95% CI) 1.12 [0.75, 1.66]
2.2 Unilateral studies 7 Odds Ratio (Random, 95% CI) 1.08 [0.64, 1.82]
3 Development of geographic
atrophy
2 148 Odds Ratio (M-H, Fixed, 95% CI) 1.30 [0.38, 4.51]
4 Visual loss of 2 to 3+ lines 8 Odds Ratio (Random, 95% CI) 0.99 [0.81, 1.22]
4.1 Bilateral studies 4 Odds Ratio (Random, 95% CI) 0.93 [0.67, 1.28]
4.2 Unilateral studies 5 Odds Ratio (Random, 95% CI) 1.17 [0.75, 1.82]
5 Loss of ≥ 0.3 log units of
contrast sensitivity at 2 years
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6 Reading speed (words/minute) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7 Drusen reduction 3 944 Odds Ratio (IV, Fixed, 95% CI) 9.16 [6.28, 13.37]
8 Subgroup analysis: development
of CNV by type of laser
10 3198 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.71, 1.23]
8.1 Argon laser 5 2340 Odds Ratio (M-H, Random, 95% CI) 0.83 [0.58, 1.20]
8.2 Diode laser 3 722 Odds Ratio (M-H, Random, 95% CI) 1.33 [0.84, 2.11]
8.3 Dye laser 2 136 Odds Ratio (M-H, Random, 95% CI) 0.51 [0.21, 1.27]
9 Subgroup analysis: development
of CNV in subthreshold
vs. visible/standard
photocoagulation
11 3720 Odds Ratio (M-H, Random, 95% CI) 1.05 [0.78, 1.41]
9.1 Subthreshold
photocoagulation
4 850 Odds Ratio (M-H, Random, 95% CI) 1.27 [0.82, 1.98]
9.2 Visible/standard
photocoagulation
8 2870 Odds Ratio (M-H, Random, 95% CI) 0.91 [0.59, 1.41]
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Analysis 1.1. Comparison 1 Photocoagulation versus control, Outcome 1 Development of choroidal
neovascularisation (CNV).
Review: Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Comparison: 1 Photocoagulation versus control
Outcome: 1 Development of choroidal neovascularisation (CNV)
Study or subgroup Photocoagulation Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Bilateral studies
CAPT 41/1008 50/1008 22.6 % 0.81 [ 0.53, 1.24 ]
DLS 12/103 7/103 7.9 % 1.81 [ 0.68, 4.80 ]
Figueroa 1994 0/30 1/30 0.9 % 0.32 [ 0.01, 8.24 ]
Little 1995 3/27 5/27 3.6 % 0.55 [ 0.12, 2.58 ]
Olk 1999 3/31 3/65 3.1 % 2.21 [ 0.42, 11.66 ]
PTAMD bilateral 2009 24/221 20/220 14.9 % 1.22 [ 0.65, 2.28 ]
Subtotal (95% CI) 1420 1453 53.0 % 0.99 [ 0.72, 1.36 ]
Total events: 83 (Photocoagulation), 86 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.65, df = 5 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.95)
2 Unilateral studies
CNVPT 12/46 13/47 8.7 % 0.92 [ 0.37, 2.31 ]
DLS 27/91 15/85 12.5 % 1.97 [ 0.96, 4.03 ]
Frennesson 1995 0/17 5/19 1.0 % 0.08 [ 0.00, 1.48 ]
Frennesson 2009 7/67 5/68 5.6 % 1.47 [ 0.44, 4.88 ]
Laser to Drusen Study 1995 6/40 11/42 6.4 % 0.50 [ 0.16, 1.51 ]
Olk 1999 4/25 7/26 4.4 % 0.52 [ 0.13, 2.05 ]
PTAMD unilateral 2002 13/63 9/71 8.5 % 1.79 [ 0.71, 4.53 ]
Subtotal (95% CI) 349 358 47.0 % 1.04 [ 0.60, 1.79 ]
Total events: 69 (Photocoagulation), 65 (Control)
Heterogeneity: Tau2 = 0.21; Chi2 = 10.20, df = 6 (P = 0.12); I2 =41%
Test for overall effect: Z = 0.14 (P = 0.89)
Total (95% CI) 1769 1811 100.0 % 1.07 [ 0.79, 1.46 ]
Total events: 152 (Photocoagulation), 151 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 15.19, df = 12 (P = 0.23); I2 =21%
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
0.01 0.1 1 10 100
Favours photocoagulation Favours control
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Analysis 1.2. Comparison 1 Photocoagulation versus control, Outcome 2 Development of CNV: sensitivity
analysis assuming moderate correlation (0.5) for bilateral studies.
Review: Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Comparison: 1 Photocoagulation versus control
Outcome: 2 Development of CNV: sensitivity analysis assuming moderate correlation (0.5) for bilateral studies
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Bilateral studies
CAPT -0.2078 (0.152766) 18.7 % 0.81 [ 0.60, 1.10 ]
DLS 0.59249 (0.356873) 10.4 % 1.81 [ 0.90, 3.64 ]
Figueroa 1994 -1.13195 (1.240966) 1.5 % 0.32 [ 0.03, 3.67 ]
Little 1995 -0.59784 (0.563085) 5.7 % 0.55 [ 0.18, 1.66 ]
Olk 1999 0.79493 (0.445526) 7.9 % 2.21 [ 0.92, 5.30 ]
PTAMD bilateral 2009 0.19744 (0.226173) 15.4 % 1.22 [ 0.78, 1.90 ]
Subtotal (95% CI) 59.6 % 1.12 [ 0.75, 1.66 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 10.50, df = 5 (P = 0.06); I2 =52%
Test for overall effect: Z = 0.54 (P = 0.59)
2 Unilateral studies
CNVPT -0.08004 (0.46806) 7.4 % 0.92 [ 0.37, 2.31 ]
DLS 0.6774 (0.36553) 10.1 % 1.97 [ 0.96, 4.03 ]
Frennesson 1995 -2.58595 (1.51919) 1.0 % 0.08 [ 0.00, 1.48 ]
Frennesson 2009 0.3754 (0.6127) 5.0 % 1.46 [ 0.44, 4.84 ]
Laser to Drusen Study 1995 -0.69851 (0.56502) 5.7 % 0.50 [ 0.16, 1.51 ]
Olk 1999 -0.44839 (0.71015) 3.9 % 0.64 [ 0.16, 2.57 ]
PTAMD unilateral 2002 0.58284 (0.47346) 7.3 % 1.79 [ 0.71, 4.53 ]
Subtotal (95% CI) 40.4 % 1.08 [ 0.64, 1.82 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 9.50, df = 6 (P = 0.15); I2 =37%
Test for overall effect: Z = 0.27 (P = 0.79)
Total (95% CI) 100.0 % 1.11 [ 0.82, 1.51 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 20.44, df = 12 (P = 0.06); I2 =41%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
0.01 0.1 1 10 100
Favours photocoagulation Favours control
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Analysis 1.3. Comparison 1 Photocoagulation versus control, Outcome 3 Development of geographic
atrophy.
Review: Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Comparison: 1 Photocoagulation versus control
Outcome: 3 Development of geographic atrophy
Study or subgroup Photocoagulation Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CNVPT 5/32 3/34 56.3 % 1.91 [ 0.42, 8.76 ]
Laser to Drusen Study 1995 1/40 2/42 43.7 % 0.51 [ 0.04, 5.89 ]
Total (95% CI) 72 76 100.0 % 1.30 [ 0.38, 4.51 ]
Total events: 6 (Photocoagulation), 5 (Control)
Heterogeneity: Chi2 = 0.81, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.4. Comparison 1 Photocoagulation versus control, Outcome 4 Visual loss of 2 to 3+ lines.
Review: Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Comparison: 1 Photocoagulation versus control
Outcome: 4 Visual loss of 2 to 3+ lines
Study or subgroup log [Odds Ratio] Odds Ratio Weight Odds Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Bilateral studies
CAPT -0.2691125 (0.1748489) 36.1 % 0.76 [ 0.54, 1.08 ]
DLS -0.573346 (0.67029815) 2.5 % 0.56 [ 0.15, 2.10 ]
Figueroa 1994 -0.3254224 (0.99673272) 1.1 % 0.72 [ 0.10, 5.09 ]
PTAMD bilateral 2009 0.18162 (0.16900101) 38.6 % 1.20 [ 0.86, 1.67 ]
Subtotal (95% CI) 78.3 % 0.93 [ 0.67, 1.28 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 4.13, df = 3 (P = 0.25); I2 =27%
Test for overall effect: Z = 0.47 (P = 0.64)
2 Unilateral studies
CNVPT -0.2772899 (0.5531024) 3.6 % 0.76 [ 0.26, 2.24 ]
DLS 0.4986213 (0.4032875) 6.8 % 1.65 [ 0.75, 3.63 ]
Laser to Drusen Study 1995 -0.1957446 (0.7104946) 2.2 % 0.82 [ 0.20, 3.31 ]
Olk 1999 -0.238411 (0.5902647) 3.2 % 0.79 [ 0.25, 2.51 ]
PTAMD unilateral 2002 0.3746934 (0.4297128) 6.0 % 1.45 [ 0.63, 3.38 ]
Subtotal (95% CI) 21.7 % 1.17 [ 0.75, 1.82 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.29, df = 4 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 100.0 % 0.99 [ 0.81, 1.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.13, df = 8 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Chi2 = 0.71, df = 1 (P = 0.40), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
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55Laser treatment of drusen to prevent progression to advanced age-related macular degeneration (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 Photocoagulation versus control, Outcome 5 Loss of ≥ 0.3 log units of contrast
sensitivity at 2 years.
Review: Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Comparison: 1 Photocoagulation versus control
Outcome: 5 Loss of≥ 0.3 log units of contrast sensitivity at 2 years
Study or subgroup Photocoagulation Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Laser to Drusen Study 1995 4/40 5/42 0.82 [ 0.20, 3.31 ]
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.6. Comparison 1 Photocoagulation versus control, Outcome 6 Reading speed (words/minute).
Review: Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Comparison: 1 Photocoagulation versus control
Outcome: 6 Reading speed (words/minute)
Study or subgroup Photocoagulation Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Laser to Drusen Study 1995 20 112.2 (28.8) 24 99.7 (37.8) 12.50 [ -7.20, 32.20 ]
-100 -50 0 50 100
Favours observation Favours photocoagulation
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Analysis 1.7. Comparison 1 Photocoagulation versus control, Outcome 7 Drusen reduction.
Review: Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Comparison: 1 Photocoagulation versus control
Outcome: 7 Drusen reduction
Study or subgroup Photocoagulation Control Odds Ratio Weight Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
CNVPT 25/30 14/31 10.1 % 6.07 [ 1.84, 20.01 ]
PTAMD bilateral 2009 177/375 34/374 86.5 % 8.94 [ 5.95, 13.43 ]
PTAMD unilateral 2002 40/79 1/55 3.5 % 55.38 [ 7.30, 420.27 ]
Total (95% CI) 484 460 100.0 % 9.16 [ 6.28, 13.37 ]
Total events: 242 (Photocoagulation), 49 (Control)
Heterogeneity: Chi2 = 3.50, df = 2 (P = 0.17); I2 =43%
Test for overall effect: Z = 11.48 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.8. Comparison 1 Photocoagulation versus control, Outcome 8 Subgroup analysis: development
of CNV by type of laser.
Review: Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Comparison: 1 Photocoagulation versus control
Outcome: 8 Subgroup analysis: development of CNV by type of laser
Study or subgroup Photocoagulation Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Argon laser
CAPT 41/1008 50/1008 41.2 % 0.81 [ 0.53, 1.24 ]
CNVPT 12/46 13/47 8.7 % 0.92 [ 0.37, 2.31 ]
Figueroa 1994 0/30 1/30 0.7 % 0.32 [ 0.01, 8.24 ]
Frennesson 1995 0/17 5/19 0.8 % 0.08 [ 0.00, 1.48 ]
Frennesson 2009 7/67 5/68 5.1 % 1.47 [ 0.44, 4.88 ]
Subtotal (95% CI) 1168 1172 56.6 % 0.83 [ 0.58, 1.20 ]
Total events: 60 (Photocoagulation), 74 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.79, df = 4 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
2 Diode laser
Olk 1999 7/56 10/91 6.9 % 1.16 [ 0.41, 3.24 ]
PTAMD bilateral 2009 24/221 20/220 18.8 % 1.22 [ 0.65, 2.28 ]
PTAMD unilateral 2002 13/63 9/71 8.5 % 1.79 [ 0.71, 4.53 ]
Subtotal (95% CI) 340 382 34.3 % 1.33 [ 0.84, 2.11 ]
Total events: 44 (Photocoagulation), 39 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
3 Dye laser
Laser to Drusen Study 1995 6/40 11/42 6.0 % 0.50 [ 0.16, 1.51 ]
Little 1995 3/27 5/27 3.1 % 0.55 [ 0.12, 2.58 ]
Subtotal (95% CI) 67 69 9.1 % 0.51 [ 0.21, 1.27 ]
Total events: 9 (Photocoagulation), 16 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Total (95% CI) 1575 1623 100.0 % 0.94 [ 0.71, 1.23 ]
Total events: 113 (Photocoagulation), 129 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.60, df = 9 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 4.27, df = 2 (P = 0.12), I2 =53%
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Analysis 1.9. Comparison 1 Photocoagulation versus control, Outcome 9 Subgroup analysis: development
of CNV in subthreshold vs. visible/standard photocoagulation.
Review: Laser treatment of drusen to prevent progression to advanced age-related macular degeneration
Comparison: 1 Photocoagulation versus control
Outcome: 9 Subgroup analysis: development of CNV in subthreshold vs. visible/standard photocoagulation
Study or subgroup Photocoagulation Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Subthreshold photocoagulation
Frennesson 2009 7/67 5/68 5.3 % 1.47 [ 0.44, 4.88 ]
Olk 1999 4/49 10/91 5.2 % 0.72 [ 0.21, 2.43 ]
PTAMD bilateral 2009 24/221 20/220 14.8 % 1.22 [ 0.65, 2.28 ]
PTAMD unilateral 2002 13/63 9/71 8.2 % 1.79 [ 0.71, 4.53 ]
Subtotal (95% CI) 400 450 33.5 % 1.27 [ 0.82, 1.98 ]
Total events: 48 (Photocoagulation), 44 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.44, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.29)
2 Visible/standard photocoagulation
CAPT 41/1008 50/1008 23.1 % 0.81 [ 0.53, 1.24 ]
CNVPT 12/46 13/47 8.4 % 0.92 [ 0.37, 2.31 ]
DLS 39/194 22/188 16.8 % 1.90 [ 1.08, 3.35 ]
Figueroa 1994 0/30 1/30 0.8 % 0.32 [ 0.01, 8.24 ]
Frennesson 1995 0/17 5/19 1.0 % 0.08 [ 0.00, 1.48 ]
Laser to Drusen Study 1995 6/40 11/42 6.1 % 0.50 [ 0.16, 1.51 ]
Little 1995 3/27 5/27 3.4 % 0.55 [ 0.12, 2.58 ]
Olk 1999 7/56 10/91 6.9 % 1.16 [ 0.41, 3.24 ]
Subtotal (95% CI) 1418 1452 66.5 % 0.91 [ 0.59, 1.41 ]
Total events: 108 (Photocoagulation), 117 (Control)
Heterogeneity: Tau2 = 0.13; Chi2 = 11.41, df = 7 (P = 0.12); I2 =39%
Test for overall effect: Z = 0.42 (P = 0.68)
Total (95% CI) 1818 1902 100.0 % 1.05 [ 0.78, 1.41 ]
Total events: 156 (Photocoagulation), 161 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 13.85, df = 11 (P = 0.24); I2 =21%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Chi2 = 1.10, df = 1 (P = 0.29), I2 =9%
0.01 0.1 1 10 100
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A D D I T I O N A L T A B L E S
Table 1. Primary analysis data including deaths and missing cases
Study Photocoagulation Observation Risk of bias due to incomplete outcome data
F S D M F S D M
CAPT 41 967 25 19 50 958 25 19 Low (bilateral)
CNVPT 12 34 2 11 13 34 3 11 Low
DLS bilat-
eral
12 91 0 2 7 96 0 2 Low (bilateral)
DLS uni-
lateral
27 72 0 0 15 70 0 0 Low
Figueroa
1994
0 30 0 0 1 29 0 0 Low (bilateral)
Frennes-
son
1995
0 17 0 2 4 15 0 0 Low
Frennes-
son
2009
7 67 NA NA 5 68 NA NA Low (see Results)
Laser
to Drusen
Study
1995
6 34 0 7 11 31 0 10 Low
Little 1995
1
3 24 NA NA 5 22 NA NA Low (bilateral)
Olk 1999
bilateral
3 28 2 10 3 62 4 5 Low (bilateral)
Olk 1999
unilateral2
4 17 NA 6 7 19 NA 4 Low
PTAMD
bilateral
2009
24 197 NA 419 20 200 NA 419 Low (bilateral)
PTAMD
unilateral
20023
13 50 5.5 55.5 9 62 5.5 43.5 High
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The assessment of the risk of bias due to incomplete outcome data is based on the graphical presentation in Figure 6 based on the
methods described in Appendix 8. In the updated version of this review, we considered missing data as at no risk of bias in bilateral
studies because a participant with paired treatment and control eyes is missed.
F: failures (choroidal neovascularisation development), S: successes, D: deaths, M: missing of unknown cause, NA: not available.
1Only last visit follow-up available and no information on when choroidal neovascularisation developed in cases with event.
2Deaths were not reported and all missing data were coded as missing of unknown cause.
3Deaths were provided overall (n = 11 at 2 years) and were equally split between assignment groups. Data at 1 or 3 years were available
and midpoints were used.
Table 2. Characteristics of the intervention and control in each study
Study ID Laser type Parameters Control
CAPT Argon 100 µm spot size/0.1 sec/60 burns Observation
CNVPT Argon 100 µm spot size/0.1 sec/ laser-20
protocol in 85% of cases
Observation
DLS Argon green/yellow dye 200 µm spot size/0.2 sec/12 burns Observation
Figueroa 1994 Argon 100 µm spot size/0.1 sec/ temporal
fovea or grid pattern
Observation
Frennesson 1995 Argon 200 µm spot size/0.05 sec/temporal
horseshoe-shaped area
Observation
Frennesson 2009 Argon green 200 µm spot size/0.05 sec/~100
spots on and between drusen
Observation
PTAMD bilateral 2009 Diode 125 µm spot size/0.1 sec/grid of 48
lesions
Observation
Laser to Drusen Study 1995 Yellow dye 50 µm spot size/0.1 sec/variable
number
Observation
Little 1995 Dye 577-620 nm 100-200 µm spot size/0.05-0.1 sec Observation
Olk 1999 Diode 125 µm spot size/0.2 sec/grid of 48
burns
Observation
PTAMD unilateral 2002 Diode 125 µm spot size/0.1 sec/grid of 48
lesions
Observation
sec: second.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Retinal Drusen
#2 drusen*
#3 (#1 OR #2)
#4 MeSH descriptor Lasers
#5 laser*
#6 MeSH descriptor Laser Coagulation
#7 photocoagulat*
#8 (#4 OR #5 OR #6 OR #7)
#9 (#3 AND #8)
Appendix 2. MEDLINE (Ovid) search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp retinal drusen/
14. drusen$.tw.
15. or/13-14
16. exp lasers/
17. laser$.tw.
18. exp laser coagulation/
19. photocoagulat$.tw.
20. or/16-19
21. 13 and 20
22. 12 and 21
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (Glanville 2006).
Appendix 3. EMBASE (Ovid) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
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11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp drusen/
34. drusen$.tw.
35. or/33-34
36. exp laser/
37. laser$.tw.
38. exp laser coagulation/
39. photocoagulat$.tw.
40. or/36-39
41. 35 and 40
42. 32 and 41
Appendix 4. ISRCTN search strategy
drusen AND laser
Appendix 5. ClinicalTrials.gov search strategy
drusen AND laser
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Appendix 6. ICTRP search strategy
drusen AND laser
Appendix 7. Estimate of the correlation coefficient of the measurements within participants in
bilateral studies
Elbourne 2002 provided a method for conducting meta-analyses of studies using paired data, such as cross-over studies or studies on
paired organs. In this appendix, we showed how we adjusted the marginal measurements, that is, with eyes as the unit of analysis
extracted from bilateral studies by the intraindividual correlation coefficient extracted from other studies in order to obtain correct
standard errors of the odds ratio.
We found both marginal and paired analyses in DLS. Data were limited to the primary outcome ’development of choroidal neovascu-
larisation (CNV)’ and to the secondary outcome ’loss of visual acuity’. In particular, Table 4 in DLS presented marginal data on CNV
occurrence, our primary outcome, and visual loss while displaying P values obtained with the McNemar test, which is based on the
Chi2 distribution and is adequate for paired data. In particular, 12/103 laser-treated eyes and 7/103 fellow eyes developed CNV and
the McNemar P value was 0.2253. The marginal P value using the Chi2 test would have been 0.2286. We considered that the ratio
of the z-values corresponding to these paired and marginal P values (1.2039 (paired) and 1.1907 (marginal)) could be used to adjust
the standard errors of the marginal logOR of CNV occurrence for laser-treated eyes compared to controls. The inverse ratio of these
two z-values was 0.9782, implying that no adjustment of the marginal logOR standard error was needed for the DLS data. Because the
marginal logOR variance was 0.4976, its value adjusted for the correlation between eyes was 0.4867, the difference between the two
being twice the covariance (which was 0.0054). From these data, the correlation coefficient could be calculated to be only 0.0451 (i.e.
0.0054*square root(12*7*96*91)/103, using the method shown in Elbourne 2002). An issue concerning this correlation coefficient
imputation is whether the coverage achieved by the McNemar test is acceptable given the possibility of cells with counts close to nil in
paired 2 x 2 tables from medium size studies such as this when events are not common.
Given the negligible effect of the correlation between eyes of the same participant for the CNV development outcome in DLS, we used
marginal data from bilateral studies as if eyes were independent units.
Using the same method for visual acuity loss, the ratio of the marginal and paired logOR standard errors was 0.8143, resulting in a
correlation coefficient of 0.2290. Therefore, for this outcome, we decided to use the inverse variance method and adjust the marginal
logOR standard error by 1.2280 (the reciprocal of the previous ratio).
We obtained a different estimate of the correlation between eyes for the CNV outcome from Little 1995. Using the formulas provided
by Elbourne 2002, the correlation coefficient was 0.69 in this small data-set using the last follow-up examination to assess the risk of
CNV occurrence. Using Elbourne 2002 notations, the numbers to calculate this value would be: s = 23, t = 2, u = 0, v = 2, hence a
= 25, b = 23, c = 2, d = 4. However, this was a very small study and was expected to estimate correlation imprecisely and also to be
affected by approximations due to low cell counts, for which common formulas for 2 x 2 tables do not hold. Thus, we did not use this
type of estimate of the correlation coefficient.
Finally, we decided to conduct a sensitivity analysis for the outcome ’development of CNV’ using a moderate correlation between eyes
of 0.5 to correct standard errors of the marginal odds ratio.
Appendix 8. Methods used to deal with incomplete outcome data
We used the following approaches to take into account the impact of missing data. In the updated version of this review, we considered
missing data as at no risk of bias in bilateral studies because a participant with paired treatment and control eyes is missed. Thus, we
only considered losses in unilateral studies.
We used Stata 13.1 software (StataCorp 2013) users’ written function ’metamiss’ assuming random uncorrelated opposite informative
missingness odds ratios (IMORs) for treatment and controls (1/2 and 2; 2 and 1/2). We assumed additional uncertainty about
log(IMOR) by setting its prior standard deviation at 1, which will result in larger 95% confidence intervals and, finally, in less weight
on studies with numerous missing data. Finally, we assumed uncorrelated IMORs of treatment and control groups when setting the
’metamiss’ command. White 2008 provides the underlying theory and a link to download ’metamiss’.
The results of these sensitivity meta-analyses on the primary analysis occurrence of CNV are shown and discussed in unilateral studies.
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WH A T ’ S N E W
Last assessed as up-to-date: 3 August 2015.
Date Event Description
3 August 2015 New citation required and conclusions have changed Issue 10, 2015: Conclusions changed from “unable to show
difference” to “treatment ineffective” for the primary out-
come development of CNV
3 August 2015 New search has been performed Issue 10, 2015: Updated searches yielded two new trials
that met the inclusion criteria (Frennesson 2009; PTAMD
bilateral 2009).
H I S T O R Y
Protocol first published: Issue 2, 2007
Review first published: Issue 3, 2009
Date Event Description
9 March 2008 Amended Converted to new review format.
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Designing the review: MBP, JE, GV.
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Data collection for the review.
• Designing search strategies: Cochrane Eyes and Vision Group.
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• Screening search results: MBP, JE, GV, DB, MM.
• Organising retrieval of papers: Cochrane Eyes and Vision Group.
• Screening retrieved papers against inclusion criteria: MBP, JE, GV, DB, MM.
• Appraising quality of papers: MBP, JE, GV, DB, MM.
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• Entering data into Review Manager 5: GV, DB, MM.
Analysis of data: GV, DB, MM, JE, MBP.
Interpretation of data.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol was originally published in 2007 and since that time there have been considerable developments in Cochranemethodology
including assessment of risk of bias and preparation of ’Summary of findings’ tables and grading of the overall quality of evidence using
GRADE. We have incorporated these developments in the review.
We have also made the following specific changes from the protocol.
• In the protocol, drusen reduction was planned to be evaluated considering the number of eyes showing at least a 50% reduction
of drusen area from the baseline aspect. However, data were sparsely reported and, therefore, we modified the protocol to allow an
extraction based on the investigators’ definition.
• In the protocol, we planned to use the risk ratio as the main effect measure but we used the odds ratio because this made it easier
to adjust for within-person correlation. See section ’Measures of treatment effect’.
• In the 2015 update, we decided that the risk of bias due to missing data was low in bilateral trials, since a pair of treatment and
control eyes would be lost, which would be unlikely to alter the odd ratio significantly. Thus, we simplified the sensitivity analysis of
missing data as described in Appendix 8.
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